人参皂苷Rb1动员骨髓内皮祖细胞防治兔自体静脉移植物再狭窄的实验研究
|
摘要
第一部分人参皂苷Rb1动员自体静脉移植兔骨髓内皮祖细胞增殖的实验研究
背景与目的
内皮祖细胞(Endothelial progenitor cells, EPCs)是内支细胞的前体细胞,是一群具有游走功能并能增殖分化的幼稚细胞,不仅可以迁移至外周血中分化为成熟内皮细胞,参与胚胎时期的血管生成、出生后的新生血管的生长,还可以存一定条件下转化为平滑肌细胞,并且能够归巢在内皮细胞受损部位,分化为内皮细胞,参与受损内皮细胞的修复,为静脉血管桥的再狭窄的预防提供了新的思路。内皮祖细胞来源广泛,且具有易于分离、增殖能力强等多方面的特点,已成为血管组织工程中一种重要的种子细胞。正常情况下成熟血管内皮细胞与内皮的损伤以及内皮祖细胞对血管内皮的修复处于一种动态的平衡之中。病理状态下,机体储备的内皮祖细胞增殖并释放入外周血,并向内皮损伤部位定向迁移、粘附,协助修复损伤的血管内皮细胞,有效的减轻静脉桥血管的再狭窄。静脉移植术后的再狭窄,末期主要是粥样硬化,而血管内皮损伤是其始动因素,内皮细胞损伤后,巨噬细胞粘附、浸入及平滑肌细胞过度增殖导致受损血管管腔狭窄或者闭塞。促进损伤血管的内皮修复可有效抑制平滑肌细胞增殖及新生内膜的形成,为治疗静脉移植血管的再狭窄提供了一个新的方向。
以往的研究发现人参皂苷Rhl能够促进内皮细胞培养基中的内皮相祖细胞的增生,但未见有关于其对骨髓中内皮祖细胞影响的报道,实验通过在建立动物血.管移植模型的基础上,观察动物股骨骨髓中内皮祖细胞表面标志CD34＋、CD133＋和VEGFR2＋的阳性表达情况,探讨人参皂苷Rb1对自体静脉移植兔骨髓内皮祖细胞增殖的影响。
材料与方法
45只清洁级新西兰兔随机分为实验组、模型组、对照组3组,每组15只。应用"no-touch"技术获取颈外静脉后,剪断颈总动脉,采用连续缝合方法端端吻合颈外静脉一颈总动脉,建立颈外静脉和颈总动脉移植的动物模型。4周后,取移植静脉血管,利用HE染色观察静脉移植血管内膜厚度以及内膜／中膜厚度比,免疫组化观察骨髓内CD34+、CD133和VEGFR2+阳性细胞情况,RT-PCR检测骨髓内CD3、CD133＋和VEGFR2阳性mRNA表达情况。
结果
1、移植静脉桥血管狭窄程度观察
石蜡切片HE染色光镜下观察分析结果显示：移植4周后的实验组、模型组、对照组血管的内膜厚度分别为(46.53±2.50)μm、(50.80±2.68)μm、(43.73±3.24)μm,各组间比较P＜0.05,实验组、模型组、对照组组间比较有统计学意义。3组静脉内膜/中膜厚度比分别为(1.96±0.06)、(2.11±0.07)、(1.81±0.09),各组间比较P＜O.05,实验组、模型组、对照组组间比较有统计学意义。
2、骨髓免疫组化CD34+、CD133和VEGFR2＋阳性细胞观察
各组移植静脉血管中可见CD34+、CD133和VEGFR2＋阳性细胞表达.4周后,实验组阳性细胞表达高于模型组,模型组阳性细胞表达高于对照组,实验组、模型组、对照组组间比较有统计学意义。
3、骨髓RT-PCRCD34+、CD133和VEGFR2基因表达情况观察
各组移植静脉血管中可见CD34＋、CD133+和VEGFR2+mRNA表达,CD34+在实验组、模型组、对照组表达的相对系数分别是(2.32±0.08)、(2.08±0.12)、(1.88±0.11),各组间比较P＜0.05,实验组、模型组、对照组组间比较有统计学意义；CD133＋在实验组、模型组、对照组表达的相对系数分别是(2.46±0.12)、(2.24±0.09)、(1.97±0.15),各组间比较0.05,实验组、模型组、对照组组间比较有统计学意义；VEGFR2＋在实验组、模型组、对照组表达的相对系数分别是(1.92±0.14)、(1.79±0.15)、(1.55±0.09),各组间比较0.05,实验组、模型组、对照组组间比较有统计学意义。
结论
1.自体静脉移植兔骨髓CD34＋、CD133+和VEGFR2+表达增强；
2.人参皂苷Rbl能够促进骨髓内皮祖细胞的增生；
第二部分人参皂苷Rb1抑制兔自体静脉移植物再狭窄的实验研究
背景与目的
冠状动脉旁路移植术(coronary artery bypass graft, CABG)是治疗冠状动脉粥样硬化性心脏病的主要方法之一,大隐静脉作为冠脉旁路移植术的主要材料,由于位置表浅,取材方便,并且有足够的长度连接主动脉与远端的冠状动脉,使其在临床上得以广泛应用。但是手术操作造成的血管内膜损伤、血流动力学改变以及炎症因子释放等一系列变化引起静脉桥血管术后再狭窄,使得静脉桥血管在临床上的应用中发现远期效果欠佳。近年来,一系列预防静脉移植血管再狭窄的方法,如药物治疗、基因治疗、血管外支架、扩张液、内皮祖细胞等应用于临床,但是均未取得明确效果。有报道称：人参皂苷Rbl对抑制静脉桥血管再狭窄有一定的积极作用。实验即是在建立自体静脉移植血管动物模型的基础上,通过腹腔注射一定剂量的人参皂苷Rbl成品,观察静脉移植血管内膜厚度的变化以及血管内膜中增殖细胞核抗原(proliferating cell nuclear antigen, PCNA)、转化生长因子(Transforming growth factor, TGF-β)和内皮型一氧化氮合酶(Endometrial nitric oxide synthase, eNOS)内变化,探讨人参皂苷Rbl对自体静脉移植血管再狭窄的抑制作用,为以后的临床应用提供理论依据。
材料与方法
45只清洁级新西兰兔随机分为实验组、模型组、对照组3组,每组15只。应用"no-touch"技术获取颈外静脉后,剪断颈总动脉,采用连续缝合方法端端吻合颈外静脉和颈总动脉,建立颈外静脉一颈总动脉搭桥的动物模型。4周后,取静脉移植血管,利用HE染色观察静脉移植血管内膜厚度以及内膜／中膜厚度比,免疫组化观察静脉移植血管增殖细胞核抗原(PCNA)阳性细胞指数、TGF-β、eNOS变化情况,RT-PeR检测静脉移植血管中TGF-β、eNOS mRNA基因的表达。
结果
1、移植静脉桥血管狭窄程度观察
石蜡切片HE染色光镜下观察分析结果显示：移植4周后的实验组、模型组、对照组血管的内膜厚度分别为(446.53±2.50)μm、(50.80±2.68)μm、(43.73±3.24)μm,各组间比较P<0.05,实验组、模型组、对照组组间比较有统计学意义。三组静脉内膜/中膜厚度比分别为(1.96±0.06)、(2.11±0.07)、(1.81±0.09),各组间比较P<0.05,实验组、模型组、对照组组间比较有统计学意义。
2、移植静脉桥血管免疫组化染色结果观察
各组移植静脉血管中可见PCNA、eNOS、TGF-β(?)日性细胞表达。移植4周后的实验组、模型组、对照组PCNA阳性表达指数分别是(40.63±2.30)、(60.45±3.38)、(19.89±2.56),各组间比较P<0.05,实验组、模型组、对照组组间比较有统计学意义。实验组、模型组、对照组TGF-β阳性表达指数分别是(18.15±4.31)、(29.28±6.37)、(12.63±3.72),各组间比较P<0.05,实验组、模型组、对照组组间比较有统计学意义。实验组、模型组、对照组eNOS阳性表达指数分别是(25.64±5.03)、(17.91±3.75)、(10.25±2.31),各组间比较P<0.05,实验组、模型组、对照组组间比较有统计学意义。
3、移植静脉桥血管RT-PCR结果观察
各组移植静脉血管可见eNOS、TGF-β基因表达。eNOS在实验组、模型组、对照组表达的相对系数分别为(2.12±0.05)、(1.98±0.09)、(1.72±0.09),eNOS在实验组中表达的相对系数高于模型组和对照组,各组间比较P<0.05,实验组、模型组、对照组组间比较有统计学意义。TGF-β在实验组、模型组、对照组表达的相对系数分别为(1.95±0.08)、(2.10±0.01)、(1.82±0.01),TGF-p在模型组中表达的相对系数高于实验组和对照组,各组间比较P<0.05,实验组、模型组、对照组组间比较有统计学意义。
结论
1内膜损伤是移植静脉血管再狭窄的始动因素,血管壁重塑是静脉血管产生再狭窄的根本原因。
2人参皂苷Rb1能够有效的防治移植静脉血管再狭窄。
3人参皂苷Rb1能够促进移植血管NOS的基因表达、抑制TGF-β基因表达。
Because of the improving of living standard and increased elderly population, the morbality of coronary atherosclerotic heart disease increased significantly in recent years, so more and more patients need coronary artery bypass graft. The materials for coronary bypass graft include arteries and venous, but because the limited of arteries and more serious hurt to get arteries graft than venous, the great saphenous vein is widely used in clinical practice as the primary material of CABG, because the great saphenous vein is superficial and easily obtained, and has enough length to connect the aorta and the far coronary artery.The autogenous vein will be restenosis after vein grafts because of endometrial injury by operative, hemodynamic changes and a series of inflammatory factors release.That make the saphenous vein is restricted
in the clinical application.In recent years,a series of methods was used for preventing vein restenosis in clinical,It was reported that Ginsenoside Rbl has some positive effect on preventing vein restenosis.After established the animal models of vein grafting, we used a certain dose of Ginsenoside Rbl by intraperitoneal injection for the animal models. By observed the changes of vein past-grafting and endothelial progenitor cells proliferation of bone marrow, to investigate the influence of ginsenoside Rb 1 on vein graft restenosis in autogenous vein graft rabbits.
Part one Expertment investigation on Ginsenoside Rbl mobilizing the endothelial progenitor cell proliferation of bone marrow in autogenous vein graft rabbits
Background and Objective
Endothelial progenitor cells(Endothelial progenitor cells, EPCs) are a group of precursor cells which functions with migration and proliferation and differentiation of naive cells can not only migrate to the peripheral blood to differentiate into mature endothelial cells involved in angiogenesis during embryonic, postnatal angiogenesis growth, under certain conditions can also be transformed into smooth muscle cells, for the vein to prevent restenosis in the bridge provides a new way of thinking. Source of progenitor cells wide, and has easy to separate, proliferation ability, and many other features, has become an important vascular tissue engineering of seed cells. Under normal circumstances mature endothelial cells and endothelial damage and endothelial progenitor cells to repair in a dynamic balance. Pathological state, the body reserves the release of endothelial progenitor cells to endothelial damage to the peripheral parts of the directional migration, adhesion, assist in the repair of vascular endothelial cell injury, effective to reduce restenosis in vein grafts. Restenosis after coronary artery bypass grafting, mainly late atherosclerosis, endothelial injury is the initial factor, endothelial cell injury, macrophage adhesion, immersion and the excessive proliferation of smooth muscle cells led to stenosis or occlusion of target vessel. Promote vascular endothelial damage repair can effectively inhibit smooth muscle cell proliferation and neointimal formation, for the treatment of restenosis vein provides a new target.
Previous studies found that ginsenoside Rbl can promote endothelial cell culture medium in the progenitor cell proliferation, this study based on animal vessel model based on the observation of animals, the femur bone marrow endothelial cell surface markers CD34+, CD 133+ and VEGFR2+ positive expression, to investigate the influence of ginsenoside Rbl on endothelial progenitor cells proliferation of bone marrow in autogenous vein graft rabbits.
Materials and Methods
45 New Zealand rabbits were randomly divided into experimental group, model group, control group 3 groups of 15 rats. Application of "no-touch" technology access after the external jugular vein, cut the carotid artery, using a continuous suture anastomosis external jugular vein and carotid artery, the establishment of external jugular vein and carotid artery bypass model. After 4 weeks, immunohistochemistry to detect bone marrow CD34+, CD133+ and VEGFR2+ positive cells in the situation, RT-PCR detection of bone marrow CD34+, CD133+ and VEGFR2+ positive mRNA expression.
Results
1. The degree of stenosis of grafted vein
The picture under-microscope showed that:After 4 weeks, the vascular intimal thickness of experimental group, model group and control group was(46.53±2.50)μm,(50.80±2.68)μm,(43.73±3.24)μm, the comparison among groups P<0.05, experimental group, model group and control group were significantly different among groups. The intimal/medial thickness ratio of three groups was (1.96±0.06), (2.11±0.07), (1.81±0.09), the comparison between groups P<0.05, the ratio of experimental group, model group and control group was significantly difference between groups.
2. Immunohistochemistry of bone marrow CD34+, CD133+ and VEGFR2+ positive cells were observed Vein graft in each group shows CD34+, CD133+ and VEGFR2+.4 weeks after positive cells, positive cells in the experimental group was higher than the model group, model group, positive cells in the control group.
3. bone marrow RT-PCRCD34+, CD133+ and VEGFR2+ gene expression observed The group transplanted veins visible CD34+, CD133+ and VEGFR2+ mRNA expression, CD34+ in the experimental group, model group and control group expressed by the relative coefficient is (2.32±0,08), (2.08±0.12), (1.88±0.11), the comparison between groups P<0.05, experimental group, model group, control group between the two groups were significantly different; CD133+ in the experimental group, model group, control the expression of the relative coefficient is (2.46±0.12), (2.24±0.09) and (1.97＝0.15), the comparison between groups P<0.05, experimental group, model group, control group between the two groups were significantly different; VEGFR2+ in the experimental group, model group, control the expression of the relative coefficient is (1.92±0.14), (1.79±0.15) and (1.55±0.09), the comparison between groups P<0.05, experimental group, model group and control group were significantly different between groups.
Conclusion
1.The expression of CD34+, CD133+ and VEGFR2+ increased significantly in autogenous graft vein rabbits.
2. Ginsenoside Rbl can promote the endothelial progenitor cells proliferation of bone marrow.
Part two Expertment investigation on Ginsenoside Rbl to prevent the restenosis of autogenous vein graft in rabbits
Background and Objective
CABG (coronary artery bypass grafting, CABG) is one of the important treatments for coronary heart disease.the great saphenous vein is widely used in clinical practice as the primary material of CABG, because the the great saphenous vein is superficial and easily obtained, and has enough length to connect the aorta and the far coronary artery.The autogenous vein will be restenosis after vein grafts because of endometrial injury by operative, hemodynamic changes and a series of inflammatory factors release.That make the saphenous vein is restricted
in the clinical application.In recent years,a series of methods was used for preventing vein restenosis in clinical, such as drug treatment, gene therapy, extravascular stent, the improve expansion fluid and endothelial progenitor cells, but the effect was so poor. It was reported that:Ginsenoside Rbl has some positive effect on preventing vein restenosis. After established the animal models of vein grafting, we used a certain dose of Ginsenoside Rbl by intraperitoneal injection for the animal models.By observed the changes of vein past-grafting, proliferating cell nuclear antigen (PCNA), transforming growth factor (Transforming growth factor, TGF-P) and nitric oxide synthase(Endothelial nitric oxide synthase, eNOS)in endometrial cells,we found that the ginsenoside Rbl has some positive effect on the vein graft restenosis inhibition. This was a basis theoretical for future clinical application.
Materials and Methods
45 New Zealand rabbits were randomly divided into three groups:the experimental group, the model group and the control group,15 rabbits in each group, "no-touch" technology was used for getting the external jugular vein. Establish the animal model with using a continuous way anastomosis external jugular vein to ipsilateral carotid artery by end-to-end fashion.4 weeks later, grafting vein was obtained as sample, the vein intimal thickness,and the intima/media thickness ratio, and the expression of TGF-βand eNOS gene was examined by RT-PCR.
Results
1. The degree of stenosis of grafted vein
The picture under-microscope showed that:After 4 weeks, the vascular intimal thickness of experimental group, model group and control group was(46.53±2.50) um,(50.80±2.68)μm,(43.73±3.24)μm, the comparison among groups P<0.05, experimental group, model group and control group were significantly different among groups. The intimal/medial thickness ratio of three groups was (1.96±0.06), (2.11±0.07), (1.81±0.09), the comparison between groups P<0.05, the ratio of experimental group, model group and control group was significantly difference between groups.
2.The results observed by immunohistochemical staining
PCNA, eNOS, TGF-P positive cells can be seen in each group grafted vein. After 4 weeks.the experimental group, model group, the control group expression of positive PCNA index were (40.63±2.30),(60.45±3.38),(19.89±2.56), The expression of TGF-p were (18.15±4.31), (29.28±6.37), (12.63±3.72) respectively, The expression of eNOS were (25.64±5.03),(17.91±3.75), (10.25±2.31)respectively, compared among the groups P<0.05. the expression of experimental group, model group and control group were significantly different among groups.
3 The results observed by RT-PCR of grafted vein
The expression of eNOS, TGF-βgene can be seen in each group grafted vein. the expression of eNOS relative coefficients in experimental group, model group, control group were (2.12±0.05),(1.98±0.09),(1.72±0.09), the expression of eNOS relative coefficient in the experimental group is higher than the model group and control group, compared among groups P<0.05, the expression of experimental group, model group and control group were significantly different among groups. The expression of TGF-βrelative coefficients in experimental group, model group, control group were (1.95±0.08),(2.10±0.01),(1.82±0.01), the expression of TGF-βrelative coefficient in the model group is higher than in the experimental group and control group, compared among groups P<0.05, the expression of experimental group, model group and control group were significantly different between groups.
Conclusion
1. Grafted vein intimal injury is the initial factor of restenosis.The remodeling of vascular is the most important reason of restenosis.
2. Ginsenoside Rbl can prevent restenosis of vein graft effectively.
3. Ginsenoside Rbl can promote NOS gene expression in grafted vein, inhibited TGF-βgene expression in grafted vein.
背景与目的
内皮祖细胞(Endothelial progenitor cells, EPCs)是内支细胞的前体细胞,是一群具有游走功能并能增殖分化的幼稚细胞,不仅可以迁移至外周血中分化为成熟内皮细胞,参与胚胎时期的血管生成、出生后的新生血管的生长,还可以存一定条件下转化为平滑肌细胞,并且能够归巢在内皮细胞受损部位,分化为内皮细胞,参与受损内皮细胞的修复,为静脉血管桥的再狭窄的预防提供了新的思路。内皮祖细胞来源广泛,且具有易于分离、增殖能力强等多方面的特点,已成为血管组织工程中一种重要的种子细胞。正常情况下成熟血管内皮细胞与内皮的损伤以及内皮祖细胞对血管内皮的修复处于一种动态的平衡之中。病理状态下,机体储备的内皮祖细胞增殖并释放入外周血,并向内皮损伤部位定向迁移、粘附,协助修复损伤的血管内皮细胞,有效的减轻静脉桥血管的再狭窄。静脉移植术后的再狭窄,末期主要是粥样硬化,而血管内皮损伤是其始动因素,内皮细胞损伤后,巨噬细胞粘附、浸入及平滑肌细胞过度增殖导致受损血管管腔狭窄或者闭塞。促进损伤血管的内皮修复可有效抑制平滑肌细胞增殖及新生内膜的形成,为治疗静脉移植血管的再狭窄提供了一个新的方向。
以往的研究发现人参皂苷Rhl能够促进内皮细胞培养基中的内皮相祖细胞的增生,但未见有关于其对骨髓中内皮祖细胞影响的报道,实验通过在建立动物血.管移植模型的基础上,观察动物股骨骨髓中内皮祖细胞表面标志CD34＋、CD133＋和VEGFR2＋的阳性表达情况,探讨人参皂苷Rb1对自体静脉移植兔骨髓内皮祖细胞增殖的影响。
材料与方法
45只清洁级新西兰兔随机分为实验组、模型组、对照组3组,每组15只。应用"no-touch"技术获取颈外静脉后,剪断颈总动脉,采用连续缝合方法端端吻合颈外静脉一颈总动脉,建立颈外静脉和颈总动脉移植的动物模型。4周后,取移植静脉血管,利用HE染色观察静脉移植血管内膜厚度以及内膜／中膜厚度比,免疫组化观察骨髓内CD34+、CD133和VEGFR2+阳性细胞情况,RT-PCR检测骨髓内CD3、CD133＋和VEGFR2阳性mRNA表达情况。
结果
1、移植静脉桥血管狭窄程度观察
石蜡切片HE染色光镜下观察分析结果显示：移植4周后的实验组、模型组、对照组血管的内膜厚度分别为(46.53±2.50)μm、(50.80±2.68)μm、(43.73±3.24)μm,各组间比较P＜0.05,实验组、模型组、对照组组间比较有统计学意义。3组静脉内膜/中膜厚度比分别为(1.96±0.06)、(2.11±0.07)、(1.81±0.09),各组间比较P＜O.05,实验组、模型组、对照组组间比较有统计学意义。
2、骨髓免疫组化CD34+、CD133和VEGFR2＋阳性细胞观察
各组移植静脉血管中可见CD34+、CD133和VEGFR2＋阳性细胞表达.4周后,实验组阳性细胞表达高于模型组,模型组阳性细胞表达高于对照组,实验组、模型组、对照组组间比较有统计学意义。
3、骨髓RT-PCRCD34+、CD133和VEGFR2基因表达情况观察
各组移植静脉血管中可见CD34＋、CD133+和VEGFR2+mRNA表达,CD34+在实验组、模型组、对照组表达的相对系数分别是(2.32±0.08)、(2.08±0.12)、(1.88±0.11),各组间比较P＜0.05,实验组、模型组、对照组组间比较有统计学意义；CD133＋在实验组、模型组、对照组表达的相对系数分别是(2.46±0.12)、(2.24±0.09)、(1.97±0.15),各组间比较0.05,实验组、模型组、对照组组间比较有统计学意义；VEGFR2＋在实验组、模型组、对照组表达的相对系数分别是(1.92±0.14)、(1.79±0.15)、(1.55±0.09),各组间比较0.05,实验组、模型组、对照组组间比较有统计学意义。
结论
1.自体静脉移植兔骨髓CD34＋、CD133+和VEGFR2+表达增强；
2.人参皂苷Rbl能够促进骨髓内皮祖细胞的增生；
第二部分人参皂苷Rb1抑制兔自体静脉移植物再狭窄的实验研究
背景与目的
冠状动脉旁路移植术(coronary artery bypass graft, CABG)是治疗冠状动脉粥样硬化性心脏病的主要方法之一,大隐静脉作为冠脉旁路移植术的主要材料,由于位置表浅,取材方便,并且有足够的长度连接主动脉与远端的冠状动脉,使其在临床上得以广泛应用。但是手术操作造成的血管内膜损伤、血流动力学改变以及炎症因子释放等一系列变化引起静脉桥血管术后再狭窄,使得静脉桥血管在临床上的应用中发现远期效果欠佳。近年来,一系列预防静脉移植血管再狭窄的方法,如药物治疗、基因治疗、血管外支架、扩张液、内皮祖细胞等应用于临床,但是均未取得明确效果。有报道称：人参皂苷Rbl对抑制静脉桥血管再狭窄有一定的积极作用。实验即是在建立自体静脉移植血管动物模型的基础上,通过腹腔注射一定剂量的人参皂苷Rbl成品,观察静脉移植血管内膜厚度的变化以及血管内膜中增殖细胞核抗原(proliferating cell nuclear antigen, PCNA)、转化生长因子(Transforming growth factor, TGF-β)和内皮型一氧化氮合酶(Endometrial nitric oxide synthase, eNOS)内变化,探讨人参皂苷Rbl对自体静脉移植血管再狭窄的抑制作用,为以后的临床应用提供理论依据。
材料与方法
45只清洁级新西兰兔随机分为实验组、模型组、对照组3组,每组15只。应用"no-touch"技术获取颈外静脉后,剪断颈总动脉,采用连续缝合方法端端吻合颈外静脉和颈总动脉,建立颈外静脉一颈总动脉搭桥的动物模型。4周后,取静脉移植血管,利用HE染色观察静脉移植血管内膜厚度以及内膜／中膜厚度比,免疫组化观察静脉移植血管增殖细胞核抗原(PCNA)阳性细胞指数、TGF-β、eNOS变化情况,RT-PeR检测静脉移植血管中TGF-β、eNOS mRNA基因的表达。
结果
1、移植静脉桥血管狭窄程度观察
石蜡切片HE染色光镜下观察分析结果显示：移植4周后的实验组、模型组、对照组血管的内膜厚度分别为(446.53±2.50)μm、(50.80±2.68)μm、(43.73±3.24)μm,各组间比较P<0.05,实验组、模型组、对照组组间比较有统计学意义。三组静脉内膜/中膜厚度比分别为(1.96±0.06)、(2.11±0.07)、(1.81±0.09),各组间比较P<0.05,实验组、模型组、对照组组间比较有统计学意义。
2、移植静脉桥血管免疫组化染色结果观察
各组移植静脉血管中可见PCNA、eNOS、TGF-β(?)日性细胞表达。移植4周后的实验组、模型组、对照组PCNA阳性表达指数分别是(40.63±2.30)、(60.45±3.38)、(19.89±2.56),各组间比较P<0.05,实验组、模型组、对照组组间比较有统计学意义。实验组、模型组、对照组TGF-β阳性表达指数分别是(18.15±4.31)、(29.28±6.37)、(12.63±3.72),各组间比较P<0.05,实验组、模型组、对照组组间比较有统计学意义。实验组、模型组、对照组eNOS阳性表达指数分别是(25.64±5.03)、(17.91±3.75)、(10.25±2.31),各组间比较P<0.05,实验组、模型组、对照组组间比较有统计学意义。
3、移植静脉桥血管RT-PCR结果观察
各组移植静脉血管可见eNOS、TGF-β基因表达。eNOS在实验组、模型组、对照组表达的相对系数分别为(2.12±0.05)、(1.98±0.09)、(1.72±0.09),eNOS在实验组中表达的相对系数高于模型组和对照组,各组间比较P<0.05,实验组、模型组、对照组组间比较有统计学意义。TGF-β在实验组、模型组、对照组表达的相对系数分别为(1.95±0.08)、(2.10±0.01)、(1.82±0.01),TGF-p在模型组中表达的相对系数高于实验组和对照组,各组间比较P<0.05,实验组、模型组、对照组组间比较有统计学意义。
结论
1内膜损伤是移植静脉血管再狭窄的始动因素,血管壁重塑是静脉血管产生再狭窄的根本原因。
2人参皂苷Rb1能够有效的防治移植静脉血管再狭窄。
3人参皂苷Rb1能够促进移植血管NOS的基因表达、抑制TGF-β基因表达。
Because of the improving of living standard and increased elderly population, the morbality of coronary atherosclerotic heart disease increased significantly in recent years, so more and more patients need coronary artery bypass graft. The materials for coronary bypass graft include arteries and venous, but because the limited of arteries and more serious hurt to get arteries graft than venous, the great saphenous vein is widely used in clinical practice as the primary material of CABG, because the great saphenous vein is superficial and easily obtained, and has enough length to connect the aorta and the far coronary artery.The autogenous vein will be restenosis after vein grafts because of endometrial injury by operative, hemodynamic changes and a series of inflammatory factors release.That make the saphenous vein is restricted
in the clinical application.In recent years,a series of methods was used for preventing vein restenosis in clinical,It was reported that Ginsenoside Rbl has some positive effect on preventing vein restenosis.After established the animal models of vein grafting, we used a certain dose of Ginsenoside Rbl by intraperitoneal injection for the animal models. By observed the changes of vein past-grafting and endothelial progenitor cells proliferation of bone marrow, to investigate the influence of ginsenoside Rb 1 on vein graft restenosis in autogenous vein graft rabbits.
Part one Expertment investigation on Ginsenoside Rbl mobilizing the endothelial progenitor cell proliferation of bone marrow in autogenous vein graft rabbits
Background and Objective
Endothelial progenitor cells(Endothelial progenitor cells, EPCs) are a group of precursor cells which functions with migration and proliferation and differentiation of naive cells can not only migrate to the peripheral blood to differentiate into mature endothelial cells involved in angiogenesis during embryonic, postnatal angiogenesis growth, under certain conditions can also be transformed into smooth muscle cells, for the vein to prevent restenosis in the bridge provides a new way of thinking. Source of progenitor cells wide, and has easy to separate, proliferation ability, and many other features, has become an important vascular tissue engineering of seed cells. Under normal circumstances mature endothelial cells and endothelial damage and endothelial progenitor cells to repair in a dynamic balance. Pathological state, the body reserves the release of endothelial progenitor cells to endothelial damage to the peripheral parts of the directional migration, adhesion, assist in the repair of vascular endothelial cell injury, effective to reduce restenosis in vein grafts. Restenosis after coronary artery bypass grafting, mainly late atherosclerosis, endothelial injury is the initial factor, endothelial cell injury, macrophage adhesion, immersion and the excessive proliferation of smooth muscle cells led to stenosis or occlusion of target vessel. Promote vascular endothelial damage repair can effectively inhibit smooth muscle cell proliferation and neointimal formation, for the treatment of restenosis vein provides a new target.
Previous studies found that ginsenoside Rbl can promote endothelial cell culture medium in the progenitor cell proliferation, this study based on animal vessel model based on the observation of animals, the femur bone marrow endothelial cell surface markers CD34+, CD 133+ and VEGFR2+ positive expression, to investigate the influence of ginsenoside Rbl on endothelial progenitor cells proliferation of bone marrow in autogenous vein graft rabbits.
Materials and Methods
45 New Zealand rabbits were randomly divided into experimental group, model group, control group 3 groups of 15 rats. Application of "no-touch" technology access after the external jugular vein, cut the carotid artery, using a continuous suture anastomosis external jugular vein and carotid artery, the establishment of external jugular vein and carotid artery bypass model. After 4 weeks, immunohistochemistry to detect bone marrow CD34+, CD133+ and VEGFR2+ positive cells in the situation, RT-PCR detection of bone marrow CD34+, CD133+ and VEGFR2+ positive mRNA expression.
Results
1. The degree of stenosis of grafted vein
The picture under-microscope showed that:After 4 weeks, the vascular intimal thickness of experimental group, model group and control group was(46.53±2.50)μm,(50.80±2.68)μm,(43.73±3.24)μm, the comparison among groups P<0.05, experimental group, model group and control group were significantly different among groups. The intimal/medial thickness ratio of three groups was (1.96±0.06), (2.11±0.07), (1.81±0.09), the comparison between groups P<0.05, the ratio of experimental group, model group and control group was significantly difference between groups.
2. Immunohistochemistry of bone marrow CD34+, CD133+ and VEGFR2+ positive cells were observed Vein graft in each group shows CD34+, CD133+ and VEGFR2+.4 weeks after positive cells, positive cells in the experimental group was higher than the model group, model group, positive cells in the control group.
3. bone marrow RT-PCRCD34+, CD133+ and VEGFR2+ gene expression observed The group transplanted veins visible CD34+, CD133+ and VEGFR2+ mRNA expression, CD34+ in the experimental group, model group and control group expressed by the relative coefficient is (2.32±0,08), (2.08±0.12), (1.88±0.11), the comparison between groups P<0.05, experimental group, model group, control group between the two groups were significantly different; CD133+ in the experimental group, model group, control the expression of the relative coefficient is (2.46±0.12), (2.24±0.09) and (1.97＝0.15), the comparison between groups P<0.05, experimental group, model group, control group between the two groups were significantly different; VEGFR2+ in the experimental group, model group, control the expression of the relative coefficient is (1.92±0.14), (1.79±0.15) and (1.55±0.09), the comparison between groups P<0.05, experimental group, model group and control group were significantly different between groups.
Conclusion
1.The expression of CD34+, CD133+ and VEGFR2+ increased significantly in autogenous graft vein rabbits.
2. Ginsenoside Rbl can promote the endothelial progenitor cells proliferation of bone marrow.
Part two Expertment investigation on Ginsenoside Rbl to prevent the restenosis of autogenous vein graft in rabbits
Background and Objective
CABG (coronary artery bypass grafting, CABG) is one of the important treatments for coronary heart disease.the great saphenous vein is widely used in clinical practice as the primary material of CABG, because the the great saphenous vein is superficial and easily obtained, and has enough length to connect the aorta and the far coronary artery.The autogenous vein will be restenosis after vein grafts because of endometrial injury by operative, hemodynamic changes and a series of inflammatory factors release.That make the saphenous vein is restricted
in the clinical application.In recent years,a series of methods was used for preventing vein restenosis in clinical, such as drug treatment, gene therapy, extravascular stent, the improve expansion fluid and endothelial progenitor cells, but the effect was so poor. It was reported that:Ginsenoside Rbl has some positive effect on preventing vein restenosis. After established the animal models of vein grafting, we used a certain dose of Ginsenoside Rbl by intraperitoneal injection for the animal models.By observed the changes of vein past-grafting, proliferating cell nuclear antigen (PCNA), transforming growth factor (Transforming growth factor, TGF-P) and nitric oxide synthase(Endothelial nitric oxide synthase, eNOS)in endometrial cells,we found that the ginsenoside Rbl has some positive effect on the vein graft restenosis inhibition. This was a basis theoretical for future clinical application.
Materials and Methods
45 New Zealand rabbits were randomly divided into three groups:the experimental group, the model group and the control group,15 rabbits in each group, "no-touch" technology was used for getting the external jugular vein. Establish the animal model with using a continuous way anastomosis external jugular vein to ipsilateral carotid artery by end-to-end fashion.4 weeks later, grafting vein was obtained as sample, the vein intimal thickness,and the intima/media thickness ratio, and the expression of TGF-βand eNOS gene was examined by RT-PCR.
Results
1. The degree of stenosis of grafted vein
The picture under-microscope showed that:After 4 weeks, the vascular intimal thickness of experimental group, model group and control group was(46.53±2.50) um,(50.80±2.68)μm,(43.73±3.24)μm, the comparison among groups P<0.05, experimental group, model group and control group were significantly different among groups. The intimal/medial thickness ratio of three groups was (1.96±0.06), (2.11±0.07), (1.81±0.09), the comparison between groups P<0.05, the ratio of experimental group, model group and control group was significantly difference between groups.
2.The results observed by immunohistochemical staining
PCNA, eNOS, TGF-P positive cells can be seen in each group grafted vein. After 4 weeks.the experimental group, model group, the control group expression of positive PCNA index were (40.63±2.30),(60.45±3.38),(19.89±2.56), The expression of TGF-p were (18.15±4.31), (29.28±6.37), (12.63±3.72) respectively, The expression of eNOS were (25.64±5.03),(17.91±3.75), (10.25±2.31)respectively, compared among the groups P<0.05. the expression of experimental group, model group and control group were significantly different among groups.
3 The results observed by RT-PCR of grafted vein
The expression of eNOS, TGF-βgene can be seen in each group grafted vein. the expression of eNOS relative coefficients in experimental group, model group, control group were (2.12±0.05),(1.98±0.09),(1.72±0.09), the expression of eNOS relative coefficient in the experimental group is higher than the model group and control group, compared among groups P<0.05, the expression of experimental group, model group and control group were significantly different among groups. The expression of TGF-βrelative coefficients in experimental group, model group, control group were (1.95±0.08),(2.10±0.01),(1.82±0.01), the expression of TGF-βrelative coefficient in the model group is higher than in the experimental group and control group, compared among groups P<0.05, the expression of experimental group, model group and control group were significantly different between groups.
Conclusion
1. Grafted vein intimal injury is the initial factor of restenosis.The remodeling of vascular is the most important reason of restenosis.
2. Ginsenoside Rbl can prevent restenosis of vein graft effectively.
3. Ginsenoside Rbl can promote NOS gene expression in grafted vein, inhibited TGF-βgene expression in grafted vein.
引文
[1]Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis[J].Science,1997;275(5302):964-967.
[2]Asahara T, Masuda H, Takahashi T, et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization[J].Circ Res,1999; 85(3):221-228.
[3]Planat-Benard V, Silvestre JS, Cousin B, et al. Plasticity of human adipose lineage cells towards endothelial cells:physiological and therapeutic perspective [J].Circulation,2004; 109(5):656-663.
[4]Hristov M, Erl W, Weber PC. Endothelial progenitor cells:mobilization, differentiation and homin [J]. Arterioscler Thromb Vase Biol,2003; 23(7):1185-1189.
[5]Hu Y, Zhang Y, Torsney E, et al. Abundant progenitor cells in the adventitia contribute to atherosclerosis of vein grafts in ApoE-deficient mice[J]J Clin Invest,2004 113(9):1249-1251.
[6]Planat-Banard V, Silvestre JS, Cousin B, et al. Plasticity of Adipose tissue:a promising therapeutic avenue in the treatment of cardiovascular and blood diseases? [J].Arch Mai CoeurVaiss,2005; 98(9):922-926.
[7]Arsic N, Mamaeva D, Lamb NJ, et al. Muscle-derived stem cells isolated as non-adherent population give rise to cardiac, skeletal muscle and neural lineages[J]. Exp Cell Res,2008; 314(6):1266-1280.
[8]Murohara T, Ikeda H, Duan J. Transplanted cord blood-derived endothelial progenitor cells augment postnatal neovascularization[J] J Clin Invest,2000,105(11):1527-1536.
[9]马良龙,黄惠民,蒋祖明,俞晓青,邹文艳.内皮祖细胞定向分化平滑肌细胞的实验研究[J].上海交通大学学报(医学版),2006；18(8)：55-58.
[10]张军霞,尤永平,傅震等.内皮祖细胞与胶质瘤关系的研究进展[J].医学研究生学报,2007,20(1)：94-96.
[11]Rafii S, Lyden D, Benezra R, et al. Vascular and hematopoietic stem cells:novel targets for anti-angiogenesis therapy? [J].Nat Rev Cancer,2002; 2(11):826-835.
[12]Miraqlia S, Godfrey W, Yin AH, et a1. A novel five-transmembrane hematopoietic stem cell antigen:isolation, characterization, and molecular cloning[J]. Blood,1997,90(12): 5013—5021.
[13]Corbeil D, Roper K, Hellwiq B, et a 1. The human AC133 hematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions[J]. J Biol Chem,2000,275(8):5512-5520.
[14]Hur J, Yoon CH, Kim HS, et al. Characterization of two types of Endothelial progenitor cells and their different contribution to neovasculogenesis[J]. Arterioscler Thromb Vase Biol,2004,24(2):288-293.
[15]Rookmaaker MB, Verqeer M, van Zonneveld AJ, et al. Endothelial progenitor cells:mainly derived from the monocyte/macrophage-containing C D34-mononuclear cell population and only in part from the hematopoietic stem cell-containing CD34+ mononuclear cell population[J]. Circulation 2003;107(8):1164-1169.
[16]Mancinelli F, Tamburini A, Spagnoli A, et al. Optimizing umbilical cord blood collection: impact of obstetric factors versus quality of cord blood units[J].Transplant Proc,2006, 38(4):1174-1176.
[17]Kaushal S, Amiel GE, Guleserian KJ, et al. Functional small-diameter neovessels created using endothelial progenitor cells expanded ex vivo[J]. Nat Med,2001; 7(9):1035-1040.
[18]Schatteman GC, Hanlon HD, Jiao C, et al. Blood-derived angioblasts accelerate blood-flow restoration in diabetic mice[J].J Clin Invest,2000;106(4):571-578.
[19]D'Arena G, Savino L, Nunziata G, et al. Immunophenotypic profile of AC133-positive cells in bone marrow, mobilized peripheral blood and umbilical cord blood[J]. Leuk Lymphoma,2002; 43(4):869-873.
[20]Hur J, Yoon CH, Kim HS, et al. Characterization of two types of endothelial progenitor cells and their different contributions to neovasculogenesis. Arterioscler Thromb Vase Biol[J].2004;24(2):288-293.
[21]Brown MA, Wallace CS, Angelos M, et al. Characterization of umbilical cord blood-derived late outgrowth endothelial progenitor cells exposed to laminar shear stress[J].Tissue Engpart A,2009; 15(11):3575-3587.
[22]Rehman J, Li J, Orschell C, et al. Peripheral blood endothelial progenitor cells are derived from monocyte/macrophages and secrete angiogenic growth factors [J]. Circulation,2003, 107 (8):1164-1169.
[23]Kocher AA, schuscter MD, Szabolcs MJ, et al. Neovascularization,of ischemic myocardium by human bone marrow derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling, and improves cardiac function[J],Nat Med,2001,7:430-436.
[24]Kaushal S, Gilad EA, Krtsine JG, et al. Fuctional small-diameter neovessels created using endothelial progenitor cells expanded ex vivo[J].Nat Med,2001; 7(9):1035-1040.
[25]Rsfii S, Meeus S, Dias S, et al. Contribution of marrow—erived progenitors to vascular and cardiac regeneration[J] Semin Cell Dev Biol,2002,13(1):61-67.
[26]Hettori K, Heissig B, Wu Y, et al. Placental growth factor reconstitutes hematopoiesis by recuriting VEGFRI(+)stem ceils from bone—arrow microenvironment[J]. Nat Med, 2002,8(8):841—849.
[27]Murayama T, Tepper OM, Silver M, et al. Determination of bone marrow-derived endothelial progenitor cell significance in angiogenic growth factor-induced neovascul arization in vivo[J]. Exp Hematol,2002,30(8):967-972.
[28]Walter DH, Rittig K, Bahlmann FH, et al. Statin therapy accelerates reendothelialization: a hovel effect involving mobilization and incorporation of bone marrow derived endothelial progenitor cells [J]. Circulation,2002,105(25):3017-3024.
[29]Badorf C, Brandes RP, Popp R, et al.Transdifferentiation of blood-derived human adult endothelial progenitor cells into functionally active cardiomyocytes[J].Circulation 2003: 107(7):1024-1032.
[30]Verama S, Kuliszewski MA, Li SH, et al. C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and runetion[J]. Circulation,2004; 109(17): 2058-2067.
[31]Stefanec T. Endothelial apoptosis:could it have a role in the pathogenesis and reatment of disease? [J]. Chest,2000; 117(3):841-854.
[32]Cosentino F, Luscher TF. Endothelial dysfunction in diabetes mellitus [J]. J Cardio Vase Phar mocol,1998; 32(Supp13):s54-s56.
[33]Wang Y, Dong Y, Li R, et al. Transmyocardial revascularization and vascular endothelial growth factor administration enhance effect of cell transplantation for myocardial infarct repair in rats[J].Coron Artery Dis,2006; 17(3):275-281.
[34]Aicher A, Zeiher AM, Dimmelerm S, et al. Mobilizing endothelial progenitor cells[J].Hypertension,2005; 45 (3):321-325.
[35]Kaushal S, Gilad EA, Krtsine JG, et al. Fuctional small-diameter neovessels created using endothelialprogenitor cells expanded ex vivo[J].Nat Med,2001; 7(9):1035-1040.
[36]Matsuo Y, Imanishi T, Hayashi Y, et al. The effect of endothelial progenitor cells on the development of collateral formation in patients with coronary artery disease[J]. Intern Med.2008; 47(3):127-134
[37]Masuda H, kalka C, Takahashi T, et al. Estrogen-mediated endothelial progenitor cell biology and kinetics for physiological postnatal vasculogenisis[J].Circ Res,2007; 101(6):598-606.
[38]Gill M, Dias S, Hattori K, et al. Vascular trauma induces rapid but transient mobilization of VEGFR2+ AC 133+ endothelial precursor cells[J],Cir Res,2001,88(2):167-174.
[39]Heissig B, Hattori K, Dias S, et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand[J]. Cell,2002; 109(5):625-637.
[40]Satoshi S, Toyoaki M. Mobilization of endothelial progenitor cells in patients with acute myocardial infarction[J]. Circulation,2001; 103(23):2776-2779.
[41]干莎莉,李静,王亚平等,人参皂甙诱导骨髓巨噬细胞表达造血生长因子的研究[J].解剖学报,2003；34(5)：500-505.
[1]Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis[J].Science,1997;275(5302):964-967.
[2]Asahara T, Masuda H, Takahashi T, et al. Bone marr ow origin of endothelial progenitor cells res ponsible for postnatal vasculogenesis in physiol ogical and pathological neovascularization[J].Circ Res,1999,85(3):2212-2228.
[3]Planat B V, Silvestre JS, Cousin B, et al.Plasticity of human adipose lineage cells towards endothelial cells:physiological and therapeutic perspective [J].Circulation,2004,109(5): 6562-6663.
[4]HristovM, ErlW, Weber PC. Endothelial progenitor cells:mobilization, differentiation and homing [J].Arteri oscler Thromb Vase Biol,2003,23(7):1185-1189.
[5]Hu Y, Zhang Y, Torsney,et al. Abundant progenitor cells in the adventitia contribute to atherosclerosis of vein grafts in ApoE2 deficient mice[J].J Clin Invest,2004,113(9): 1258-1265.
[6]Planat-Banard V,Silvestre JS,Cousin B,et al.Plasticity of Human Adipose Lineage cells towards endothelial cells plysiological and therapeutic perspectivers[J].Circulationg,2004, 109:656-663.
[7]Arsic N, Mamaeva D, Lamb NJ, et al. Muscle-derived stem cells isolated as non-adherent population give rise to cardiac, skeletal muscle and neural lineages[J]. Exp Cell Res,2008, 314(6):1266-1280.
[8]Murohara T, Ikeda H, Duan J. Transplanted cord blood2 derived endothelial progenitor cells augment postnatal neovascularization[J].J Clin Invest,2000,105(11):1527-1536.
[9]马良龙,黄惠民,蒋祖明,俞晓青,邹文艳.内皮祖细胞定向分化平滑肌细胞的实验研究[J]上海交通大学学报(医学版),2006；18(8)：55-58.
[10]张军霞,尤永平,傅震等.内皮祖细胞与胶质瘤关系的研究进展[J].医学研究生学报,,2007,20(1)：94-96.
[11]Rafii S, Lyden D, Benezra R, et al. Vascular and hematopoietic stem cells:novel targets for anti-angiogenesis therapy? [J].Nat Rev Cancer,2002,2(11):826-835.
[12]Holyoake TL. Alcom MJ. CD34+positive haemopoietic cells:biology and clinical applications[J]. Blood Rev,1994,8(2):113-124.
[13]Miraglia S, Godfrey W, Yin AH, et al. A A novel five-transmembrane hematopoietic stem cell antigen:isolation,characterization,and molecular cloning[J]. Blood,1997,90(12): 5013-5021.
[14]Corbeil D, Roper K,Hellwig et al. The human AC133 hematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions[J]. J Biol Chem,2000,275(8):5512-5520.
[15]Jin H, Chang2Hwan Y, Hyo2Soo K, et al. Characterization of two types of Endothelial p rogenitor cells and their different contribution to neovasculogenesis[J]. Arterioscler Thromb Vase Biol,2004; 24(2):288-293.
[16]Rookm aaker M B,Vergeer M,van Zonneveld AJ,et al.Endothelial progenitor cells:m ainly derived from themonocytem acrophage-containing CD 34 mononuclear cell population and only in part from the hem atopoietic stem cell-containing CD34+ mononuclear cell population[J]. Circulation 2003;108(21):el50.
[17]Mancinelli F, Tamburini A, Spagnoli A, et al. Optimizing um-bilical cord blood collection: impact of obstetric factors versus quality of cord blood units[J].Transplant Proc,2006,38(4): 1174-1176.
[18]Kaushal S, Gilad EA, Krtsine JG,et al. Fuctional small-diameter neovessels created using endothelialprogenitor cells expanded ex vivo[J].Nat Med,2001; 7(9):1035-1040.
[19]Schattem an G C,H anlon H D,Jiao C,et al.Blood-derived angioblasts accelerate blood-flow restoration in diabeticmice[J]. J C lin Invest2000;106(4):571-578.
[20]Arena G, Savino L, Nunziata G, et al. Immunophenotypic profile of AC133-positive cells in bone marrow,mobilized rleripheral blood and umbilical cord blood. Leuk Lymphoma,2002,43(4):869-873.
[21]J in H, Chang2Hwan Y, Hyo2Soo K, et al. Characterization of two types of Endothelial progenitor cells and their different contribution to neovasculogenesis [J]. Arterioscler Thromb Vasc Biol,2004,24(2):288-293.
[22]Hur J, Yoon CH, Kim HS, et al. Characterization of two types of endothelial progenitor cells and their different contributions to neovasculogenesis [J]. Arterioscler Thromb Vase Biol,2004;24(2):288-293.
[23]Rehman J,Li J,Orschell C,et al,Peripheral blood endothelial progenitor cells are derived from monocyte/macrophages and secrete angiogenic growth factors [J].circulation,2003, 107:1164-1169.
[24]Kocher AA,schuscter MD,Szabolcs MJ,et al,Neovascularization,of ischemic myocardium by human bone marrow derived angioblasts prevents cardiomyocyte apoptosis,reduces remodeling,and improves cardiac function [J].Nat Med,2001,7:430-436.
[25]Kaushal S, Gilad EA, Krtsine JG,et al. Fuctional small-diameter neovessels created using endothelialprogenitor cells expanded ex vivo[J]. Nat Med,2001; 7(9):1035-1040.
[26]Rsfii S, Meeus S, Dias S, et a 1. Contribution of marrow—erived progenitors to vascular and cardiac regeneration [J].Semin Cell Dev Biol,2002; 13(1):61-67.
[27]Hettori K, Heissig B, Wu Y, et al. Placental growth factor reconstitutes hematopoiesis by recuriting VEGFRI(+)stem ceils from bone-marrow microenvironment[J]. Nat Med,2002; 8(8):841-849.
[28]Murayama T, Tepper OM, Silver M, et al. Determination of bone marrow—erived endothelial progenitor cell significance in angiogenic growth factor-induced neovasculari-zation in vivo[J]. Exp Hematol,2002; 30(8):967-972.
[29]Walter DH, Rittig K, Bahlmann FH, et al. Statin therapy accelerates reendothelialization: a hovel effect involving mobilization and incorporation of bone marrow derived endothelial progenitor cells [J]. Circulation,2002; 105(25):3017-3024.
[30]Badorf C, Brandes RP, Popp R, et al.Transdifferentiation of blood-derived human adult endothel ial progeni tor cells into functionally active cardiomyocytes[J]. Circulation, 2003; 107(7):1024-1032.
[31]Verama S, Kuliszewski MA, Li SH, et al. C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and runetion[J]. Circulation,2004; 109(17): 2058-2067.
[32]Stefanec T. Endothelial apoptosis:could it have a role in the pathogenesis and reatment of disease[J]? Chest,2000; 117(3):841-854.
[33]Cosentino F,Luscher TF. Endothelial dysfunction in diabetes mellitus [J]. J Cardio Vase Pharmocol,1998; 32(Suppl3):s54-s56.
[34]Wang Y, Dong Y, Li R, et al.Transmyocardial revascularization and vascular endothelial growth factor administration enhance effect of cell transplantation for myocardial infarct repair in rats[J].Coron Artery Dis,2006; 17(3):275-281.
[35]Aicher A,Zeiher AM,Dimmelerm S,et al,Mobilizing endothelial progenitor cells[J]. Hypertension 2005; 45(3):321-325.
[36]Kaushal S, Gilad EA, Krtsine JG,et al. Fuctional small-diameter neovessels created using endothelialprogenitor cells expanded ex vivo[J]. Nat Med,2001; 7(9):1035-1040.
[37]Matsuo Y, Imanishi T, Hayashi Y, et al. The effect of endothelial progenitor cells on the development of collateral formation in patients with coronary artery disease[J]. Int Med. 2008; 47(3):127-134.
[38]Masuda H,kalka C,Takahashi T,et al,Estrogen-mediated endothelial progenitor cell biology and kinetics for physiological postnatal vasculogenisis[J]. Circ Res,2007 101(6):598-606.
[39][39]Muhammad G,Sergio D,Koichi H,et al,Vasculartrauma induces rapid but transcient mobilization of VEGFR2+ AC133+ endothelial precursor cells[J].Cir Res,2001; 88(2):167-174.
[40]Heissig B,Hattori K,Dias S,et al,Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand[J]. Cell,2002; 109(5):625-637.
[41]Satoshi S,Toyoaki M,Mobilization of endothelial progenitor cells in patients with acute myocardial infarction[J]. circulation,2001; 103(23):2776-2779.
[42]Werner N, Kosiol S, Schiegl T, et al. Circulating endothelial progenitor cells and cardiovascular outcomes[J]. N Engl J Med,2005; 353(10):999-1007.
[43]Matsuo Y, I manishi T, Hayashi Y, et al. The effect of senescence of endothelial p rogenit or cells on instent restenosis in patients undergoing coronary stenting [J].Int Med,2006; 45(9):581-587.
[44]Gerhar dM, Roddy MA, Greager SJ, et al. Ageing progressively impairs endothelium- dependent vascdilation in forearm resistance vessels of human[J].Human,1996:27(4): 849-853.
[45]Cosentino F, Luscher TF. Endothelial dysfunction in diabetes mellitus [J]. J Cardio Vase Phar mocol,1998; 32(Supp13):s54-s56.
[46]Wang Y, Dong Y, Li R, et al. Transmyocardial revascularization and vascular endothelial growth factor administration enhance effect of cell trans p lantati on for myocardial infarct repair in rats[J]. Coron Artery Dis,2006; 17(3):275-281.
[47]Lowe HC, Oesterle S N, Khachigian LM. Coronary in stent restenosis:Current status and future strategies[J]. J Am Coll Cardiol,2002; 39(2):183-193.
[48]Yoon YS, Lee N, Scadova H. Myocardial regenerati on with bone marrow derived stem cells [J]. Biol Cell,2005; 97(4):253-263.
[49]张威,周莉,金惠铭等.用CD133免疫磁珠分离脐血内皮祖细胞的实验研究[J].中国病理生理杂志,2005；21(9)：1675-1680.
[50]Jacob G, Itzhak H, Emil G, et al. Number and adhesive properties of circulating endothelial progenitor cells in'patients within stent restenosis [J]. Arteri oscler Thromb Vase Biol, 2003: 23(12):e52-e60.
[51]Okazaki T, Ebihara S, Asada M,et al. Granulocyte colony stimulating factor promotes tumor angiogenes is via increasing circulating endothelial progenitor cells and Grl+CD11b+cells in cancer animal models[J]. Int Immunol 2006; 18(1):1-9.
[52]肖海波.转染VEGF基因的内皮祖细胞移植丁缺血心肌的试验研究[D].第二军医大学博士学位论文,2004.
[53]Schachinger V, Assmus B, Britten MB, et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction:final one-year results of the TOPCARE-AMI Trial[J].J Am Coll Cardiol,2004; 44(8):1690-1699.
[54]Okazaki T, Ebihara S, Asada M, et al. Granulocyte colony-stimulating factor promotes rumor angiogenes is via increasing circulating endothelial progenitor cells and Grl+CD11b+ cells in cancer animal models[J]. Int Immunol 2006; 18(1):1-9.
[55]Asahara T,Murasawa S. Endothelial progenitor cells for Vasculogenesis [J]. Physiology, 2005:20(2):36-42.
[56]Zeng L, Xiao Q, Margariti A, et al. HDAC3 is crucial in shear and VEGF-induced stem cell differentiation toward endothelia cells[J].Cell Biol,2006; 174(7):1059-1069.
[57]Erik BF, Katrin W. CD34-/CD133+/VEGFR-2+ Endothelial Progenitor Cell Subpopulation With Potent Vasoregenerative Capacities[J].Circ Res 2006:98(3):20-25.
[58]Gries e DP, Ehsan A, Luis G,et al.Isolation and Transplantation of Autologous Circulating Endothelial Cells into denuded vessels and prosthetic grafts:Implications for Cell-Based Vascular Therapy[J].Circulation,2003; 108(21):2710-2715.
[59]Asahara T, Takahashi T, Masuda H, et al. VEGF contribute to postnatal neovascularization by mobilizing bone marrow derived endothelial progenitor cells[J]. EMBO,1999; 18(14): 3964-3972.
[60]Rabatti D. The involvement of endothelial progenitor cells in tumor angiogenesis [J]. J Cell Mol Med,2004; 8(3):294-300.
[61]Aicher A, Zeiher AM, Dimmelerm S, et al. Mobilizing endothelial progenitor cells[J]. Hypertension,2005; 45 (3):321-325.
[1]Brener SJ,Lytle B, Casserly IP, et al.Propensity analysis of long-term survival after surgical or percutaneous revascularization in patients with multivessel coronary artery disease and high-risk features[J]. Circulation,2004,109(19):2290-2295.
[2]Aear C, Jevara VA, Portoghese M, et al. Revival of the radial artery For coronary artery bypass grafting[J]. Ann Thorac Surg,1992,54:652-659.
[3]Grondin CM, Campeau L, Lesperanee J, et al. Atherosel erotic changes in coronary vein grafts 6 years after operation:angiographie aspect in 110 patients[J].J Thoac Cardiovasc Surg,1979,77:24-31.
[4]Weintraub WS, Jones EL, Carver JM. Frequency of repeat coronary bypass or coronary angioplasty after coronary artery bypass surgery using saphenous venous grafts[J]. Am J Cardiol,1994,73:103-112.
[5]何飞,孙明等。通脉汤对损伤的血管内皮细胞NO生成及纤溶平衡的影响[J].J China Physician,2004,6(1):66-69.
[6]Favaloro RG. Landmarks in the development of coronary artery bypass surgery[J], Circulation.1998,98(5):466-478.
[7]Canver CC, Conduit options in coronary artery bypass[J].Surgery Chest.1995,108: 1150-1155.
[8]Eagle KA.Guyton RA,Davidoff R,et al.ACC/AHA guidelines for coronary artery bypass graft surgery:executive summary and recommendations:A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines(Committee to revise the 1991 guidelines for coronary artery bypass graft surgery [J]. Circulation,1999, 100(13):1464-1480.
[9]Tian XD, Zhou NK, Li BJ, et al.Effects and mechanisms of non-restrictive external stent for prevention of vein graft restenosis in a rabbit model. Chin Med J。 2010; 123(17):2400-2404.
[10]Handa M, Li W, Morioka K, et al.Adventitial delivery of platelet-derived endothelial cell growth factor gene prevented intimal hyperplasia of vein graft. J Vase Surg.2008 Dec;48(6):1566-1574.
[11]Domingos S.R. Souza, Michael R. Dashwood, Janice C.S. Tsui, et al.ImProved Patency in vein grafts harvested with surrounding tissue:results of a randomized study using three harvesting techniques. Ann Thorac Surg,2002,73:1189-1195.
[12]Del Rizzo DF, Moon MC, Werner JP, et al. A novel organ culture method to study intimal hyperplasia at the site of a coronary artery bypass anastomosis.Ann Thorac Surg. 2001:71:1273-1280.
[13]Miketic S, Carlsson J, Tebbe U. Influence of gradually increased slow balloon inflation on restenosis after coronary angioplasty. Am Heart J 1998 Apr:135(4):709-713.
[14]Zhang L,Ma Y,Zhang J,et al.A new cellular signaling mechanism for angiotensin Ⅱ activation of NF-kappaB:An IkappaB-independent, RSK-mediated phosphorylation of p65[J].Arterioscler Thromb Vase Biol,2005,25(6):1148-1153.
[15]Lopes RD,Hafley GE,Allen KB,et al.Endoscopic versus open vein-graft harvesting in coronary-artery bypass surgery[J].N Engl JMed,2009,361(3):235-244.
[16]Ellis,SG,Chen MS,Jia G,et al.Relation of polymorphisms in five genes to long-term aortocoronary saphenous vein graft patency[J].Am J Cardiol 2007,99(8):1087-1089.
[17]肖明第,尤文俊,袁忠祥等,冠状动脉旁路移植术后影响静脉移植物内膜增生因素的实验研究[J].中华医学杂志,2002,82(22)：1550-1552.
[18]Joseph G, Motwani and Eric J. Topol. Aortocoronary Saphenous vein graft disease: Pathogenesis, Predisposition, and Prevention[J]. Circulation,1998,97:916-931.
[19]Hemant S,Thatte and ShukriF. Khuri.The coronary artery bypass conduit:1. Intraoperative endothelial injury and its implication on graft patency. Ann Thorac Surg,2001, 72:2245S-2252S.
[20]Jeffrey H. Shuhaiber, Alexander N. Evans, Malek G. Massad*.et al·Mechanisms and future directions for prevention of vein graft failure in coronary bypass surgery. European Journal of Cardio-thoracic Surgery 2002,22:387-396.
[21]hafi S, Palinski W, Born GVR. Comparison of uptake and degradation of low density lipoproteins by arteries and veins of rabbits[J]. Atherosclerosis,1987,66:131-138.
[22]Gracia RL, Coltrera, Gown AM. Analsis of proliferative grade using anti-PCNA monoclonal antibodies in fixed, embedded tissue.Ann J Pathol.1989;134:733-739.
[23]Speir E, Epstein SE.Inhibition of smooth muscle cell proliferation by an antisense oligodeoxynueleotide targeting the message rRNA encoding prolifering cell nuelear antigen[J]. Circulation,1992,86:538-544.
[24]Alan Fine, Ronald H.Goldstein.The effect of TGF — beta on cell proliferation and collagen formation by lung fibroblasts. J BioChem.1987;262(8):3897-3902.
[25]Clardio KuPfahl, Daniel Pink, Katharina Friedrich, et al.angiotensin Ⅱ directly increases transforming grovth factorβl and osteopontin and indirectly affects collagen mRNA expression in the human heart.Cardiovasc Res.2000;46:463-475.
[26]William Durante, Lan Liao, Sylvia V, et al.Transforming growth factor-betal Stimulates L-arginine transport and metabolism in vascular smooth muscle cells.Cireulation2001;103: 1121-1127.
[27]Siow R C, Mallawarachchi C M,Weissberg PL. Migration of adventitial myofibroblasts following vascular ballooninjury:insights from in vivo gene transferto rat carotid arteries [J]. Cardiovasc Res,2003,59(1):212-221.
[28]Tashiro H, Shimokawa H, Sadamatn K, etal. Prognostic significance of plasmaconcentra-tions of transforming growthfactor-beta 1 in patients with coronaryartery disease[J]. Coron Artery Dis,2002,13(3):139-143.
[29]Hao J,Ju H,Zhao S,et al. Elevation of expression of Smads 2,3 and 4, decorin and TGF-β in the chronic phase of myocardial infarct scar healing [J].J Mol Cell Cardio,1999,31(3): 667-678.
[30]Smith J D,Bryant S R,Couper L L,et al. Soluble transforming growth factor-beta type Ⅱ receptor inhibits negative remodeling, fibroblast transdifferentiation, and intimal lesion formation but not endothelial growth[J]. Cir Res,1999,84(10)1212-1222.
[31]Lindner V.vascular repair process is mediated by transforminggrowth factorbeta[J]. Z Kardiol,2001,90(Suppl 3):17-22.
[32]Toprak V, Sirin BH, Tok D, et alThe effect of cardiopulmonary bypass on the expression of inducible nitric oxide synthase, endothelial nitric oxide synthase, and vascular endothelial growth factor in the internal mammary artery[J].J Cardiothorac Vase Anesth.2006;20(1): 63-67.
[33]郑家豪,镡朝晖,穆军升等,eNOS基因转染预防静脉移植血管再狭窄[J]. 中国心胸血管外科临床杂志,2003,10(2)：81-84.
[34]Luttun A, Carmeliet G,Canneliet P.Vascular progenitors:from biology to treatment[J]. Trends Cardiovasc Med,2002,12:88-96.
[35]Shi Q, Rafii s,Wu MH,et al.Evidence for circulating bone marrow derived endothelial cells[J].Blood,1998,92:362-367.
[36]Werner N, Priller J, Laufs U. et al.Bone marrow-derived progenitor cells modulate vascular reendothelialization and neointimal formation:effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition. Arterioscler Thromb Vase Biol,2002,22:1567-1572.
[37]Luseher TF, Barton M.Biology of the endothelium. ClinCardiol,1997,20(11 suppl 2):3-10.
[38]Miller Kasprzak E, Jagodzinski PP. Endothelial progenitor cells as a new agent contributing to vascular repair. Arch Immunol Ther Exp (Warsz).2007 Jul-Aug; 55(4):247-59.
[39]Loomans CJM, de Koening EJP, Stal FJT, et al. Endothelial progenitor cell dysfunction. A novel concept in the pathogenesis of vascular complications of type I diabetes.Diabetes.2004,53:195-199.
[40]Strehlow K,Werner N, Berweiler J, t al. Estrogen increases bone marrow-derived endothelial progenitor cell production and diminishes neointima formation. Circulation.2003; 107(24):3059-3065.
[41]Thum T, Fraccarollo D, Schultheiss M. et al. Endothelial nitric oxide synthase uncoupling impairs endothelial progenitor cell mobilization and function in diabetes.Diabetes.2007; 56(3):666-74.
[42]王莎莉,李静,王亚平等,人参包甙诱导骨髓巨噬细胞表达造血生长因子的研究[J].解剖学报,2003,34(5)：500-505.
[43]谢薇,夏凌辉,方峻等,人参皂苷Rb1对人脐静脉内皮细胞一氧化氮释放和TGF-β1表达的影响和意义[J］.中国医院药学杂志,2007,27(9)：1225-1228.
[1]Brener SJ,Lytle B,Casserly IP,et al. Propensity analysis of long-term survival after surgical or percutaneous revascularization in patients with multivessel coronary artery disease and high-risk features[J]. Circulation,2004; 109(19):2290-2295.
[2]Eagle KA, Guyton RA,Davidoff R,et al.ACC/AHA guidelines for coronary artery bypass graft surgery:executive summary and recommendations:A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines(Committee to revise the 1991 guidelines for coronary artery bypass graft surgery[J].Circulation,1999; 100(13):1464-1480.
[3]Domingos S.R, Souza, Michael R, et al.Improved Patency in vein grafts harvested with surrounding tissue:results of a randomized study using three harvesting techniques[J]. Ann Thorac Surg,2002; 73:1189-1195.
[4]潘文标,郑家豪,连锋等.静脉桥狭窄实验动物模型的建立[J].现代医学,2006；34(1)：6-8.
[5]Qiao A, Zeng Y, Xu X. Comparisons of hemodynamics in 1-way and 2-way CABG[J].J Biomed Eng,2006; 23(2):295-299.
[6]Verrier ED, Boyle EM Jr. Endothelial cell injury in cardiovascular surgery[J].Ann Thorac Surg,1996; 62:915-922.
[7]Nachman RL, Silverstein R.Hypercoagulable state[J]s. Ann Intern Med,1993; 119:819-827.
[8]Eric Allaire, Alexander W, Clowes. Endothelial cell Injury in Cardiovascular Surgery:The Intimal Hyperplastic Response[J]. Ann Thorae Surg,1997; 63:582-591.
[9]Zhang L,Ma Y,Zhang J,et al.A new cellular signaling mechanism for angiotensin Ⅱ activation of NF-kappaB:An IkappaB-independent, RSK-mediated phosphorylation of p65 [J]. Arterioscler Thromb Vase Biol,2005; 25(6):1148-1153.
[10]Lopes RD, Hafley GE, Allen KB, et al. Endoscopic versus open vein-graft harvesting in coronary-artery bypass surgery[J].N Engl J Med,2009; 361(3):235-244.
[II]Parang P, Arora R. Coronary vein graft disease:pathogenesis and prevention[J].Can J Cardio!,2009; 25(2):e57-62.
[12]Ellis SG, Chen MS, Jia G,et al.Relation of polymorphisms in five genes to long-term aortocoronary saphenous vein graft patency[J].Am J Cardiol 2007; 99(8):1087-1089.
[13]萧明第,尤文俊,袁忠祥等.冠状动脉旁路移植术后影响静脉移植物内膜增生因素的实验研究中华医学杂志,2002；82(22)：1550-1552.
[14]Durante W, Liao L, Reyna SV, et al. Transform in growth factor-β1 stimulates L-arginine transport and metabolism in vascular smooth muscle cells [J].Circulation,2001; 103(8):1121-1127.
[15]Joseph G, Motwani, Eric J, et al. Aortocoronary Saphenous vein graft disease: Pathogenesis, Predisposition, and Prevention[J]. Circulation.1998：97:916-931.
[16]Hemant S, Thatte, Shukri F. Khuri.The coronary artery bypass conduit:Intraoperative endothelial injury and its implication on graft patency[J]. Ann Thorac Surg,2001; 72:2245S-2252S.
[17]Jeffrey H, Shuhaiber, Alexander N，et al. Mechanisms and future directions for prevention of vein graft failure in coronary bypass surgery[J]. Eur J Cardio Thorac Surg,2002; 22:387-396.
[18]Hafi S, Palinski W, Born GVR. Comparison of uptake and degradation of low density lipoproteins by arteries and veins of rabbits[J]. Atherosclerosis,1987; 66:131-138.
[19]Larson RM, Hagen PO, Fuehs JCA. Lipid biosynthesis in arteries, veins and venous grafts[J].Circulation,1974; 50(supplIII):131-139.
[20]Stein PD, Dalen JE, Goldman S, et al. Antithrombotic therapy in patients with saphenous vein and internal mammary artery bypass grafts[J].Chest,1995; 108(4):424S-430S.
[21]Dacey LJ, Munoz JJ, Johnson ER, et al. Effect of preoperative aspirin use on mortality in coronary artery bypass grafting patients[J].Ann Thorac Surg,2000; 70(6):1986-1990.
[22]Stein PD, Dalen JE, Goldman S, et al. Antithrombotic therapy in patients with saphenous vein and internal mammary artery bypass grafts[J]. Chest 2001,119(SuppI.l):278S-282S.,
[23]王新文,张强,王斌.肝素对自体移植静脉内膜增殖的影响.中国实用外科杂志,1999；19(4)：230-231.
[24]Porter KE, Turner NA, Titus JL, et al. Statins for the prevention of vein graft stenosis:a role for inhibition of matrix metalloproteinase-9[J]. Biochem Soc Trans,2002; 30(2):120-126.
[25]Knatterud GL, Rosenberg Y, Campeau L,et al. Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial. Post CABG Investigators [J].Circulation,2000; 102(2):157-165.
[26]Frick M, Dulak J, Cisowski J，et al. Statins differentially regulate vascular endothelial growth factor synthesis in endothelial and vascular smooth muscle cells[J]. Atheros clerosis,2003; 170(2):229-236.
[27]Motayama K, Fukumoto S, Koyama H, et al. SREBP inhibits VEGF expression in human smooth muscle cells[J].Biochem Biophys Res Commun,2006; 342(1):354-360.
[28]Cucina A, Borrelli V, Randone B, et al. Vascular endothelial growth factor increases the migration and proliferation of smooth muscle cells through the mediation of growth factors released by endothelial cells [J]. J Surg Res,2003; 09(1):16-23.
[29]Manfred L, Marco C, Markus H, et al. ACE inhibitor and AT(1) antagonist blockade of deformation-induced gene expression in the rabbit jugular vein through beta(2) receptor activation[J]. Arterioscler Thromb VasC Biol, Dallas,2001; 61-66.
[30]Sullivan JM, El-Zeky F, Vander Zwaag R, et al. Effect on survival ofEstrogen replacement therapy after coronary artery bypass grafting[J].Am J Cardiol,1997; 79:847-850.
[31]Jeffrey H. Shuhaiber. Alexander N, et al. Mechanisms and future directions for prevention of vein graft failure in coronary bypass surgery[J]. Eur J Cardio Thorac Surg,2002; 22:387-396.
[32]Andrew F, Phillip F, Heller S, et al. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent[J].Circulation,2001; 104 (4):473-481.
[33]Stark VK, Hoch JR, Warner TF. Monocyte chemotactic protein-1 expression is associated with the development of vein graft intimal hyperplasia[J]. Arterioscler Thromb Vase Biol,1997; 17(8):1614-1621.
[34]郑家豪,镡朝晖,穆军升等.eNOS基因转染预防静脉移植血管再狭窄[J].中国心胸血管外科临床杂志,2003；10(2)：81-84.
[35]迟立群,李功宋,高长青等,野生型p53基因转染和低能量激光照射防治移植静脉再狭窄的实验研究[J].中华胸心血管外科杂志,2003；19(1)：50-52.
[36]George SJ, Angelini GD, Capogrossi MC, et al. Wild-type p53 gene transfer inhibits neointima fonnation in human saphenous vein by modulation of smooth muscle cell migration and induction of apoptosis [J].Gene Therapy,2001:8(9):668-676.
[37]Johnson JL, Van Eys GJ, Angelini GD, et al. Injury induces dedifferentiation of smooth muscle cells and increased matrix-degrading metalloproteinase activity in human saphenous vein[J].Arterioscler Thromb Vase Biol,2001; 21(7):1146-1151.
[38]Joseph G, Motwani and Erie J, Topol. Aortocoronary Saphenous vein Graft Disease: Pathogenesis, PredisPosition, and Prevention[J]. Circulation,1998; 97:916-931.
[39]Mary Beth Deyoung, David A.Diehek.Gene Therapy for Restenosis. Are We Ready[J] Circ Res,1998; 82:306-313.
[40]Luttun A, Carmeliet G,Canneliet P.Vascular progenitors:from biology to treatment[J],Trends Cardiovasc Med,2002,12:88-96.
[41]Wern N, Junk S, Laufs U, et al. Intravenous transfusion of endothelial Progenitor cells reduces neointima formation after vascular injury[J].Circ Res,2003; 93(2):e 17-e24.
[42]Fujiyama S, Amano K, Uehira K, et al. Bone marrow monocyte lineage cells adhere on injured endothelium in a monocyte chemoattractant Protein-l-dependent manner and accelerate reendothelialization as endothelial progenitor cells[J].Circ Res,2003: 93(10):980-989.
[43]Kaushal S, Amiel GE, Guleserian KJ, et al. Functional small-diameter neovessels created using endothelial Progenitor cells expanded ex vivo[J].Nat Med,2001; 7(9):1035-1040.
[44]Kong D, Melo LG, Mangi AA,et al. Enhanced inhibition of neointimal hyperplasia by genetically engineered endothelia Progenitor cells[J]. circulatron,2004; 109(14):1769-1775.
[45]Shi Q, Rafii s,Wu MH,et al.Evidence for circulating bone marrow derived endothelial cells[J].Blood,1998; 92:362-367.
[46]Werner N, Priller J, Laufs U, et al.Bone marrow-derived progenitor cells modulate vascular reendothelialization and neointimal formation:effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition[J].Arterioscler Thromb Vase Biol,2002,22:1567-1572.
[47]王立新,王奇,石海燕等.造血干细胞动员对移植静脉近期通畅率的影响[J].中囯胸心血管外科临床杂志,2007,14(1)：4l-45.
[48]王莎莉,李静,王亚平等.人参皂甙诱导骨髓巨噬细胞表达造血生长因子的研究[J].解剖学报,2003；34(5)：500-505.
[49]谢薇,夏凌辉,方峻等.人参皂茁Rb1对人脐静脉内皮细胞一氧化氮释放和TGF-β1表达的影响和意义[J].中国医院药学杂,2007；27(9)：1225-1228.
[50]Parsonnet V, Lari AA, Shah IH. New stent for support of veins in arterial grafts[J].Arch Surg,1963; 87(4):696-702.
[51]Liu SQ, Biomechancial basis of vascular tissue eng ineering[J].Crit Rev Biomed Eng,1999; 27(12):75-148.
[52]Karayannacos PE, Hosteller JR, Bond MG,et al. Late failure in vein grafts:mediating factors in subendothelial fibromuscular hyperplasia[J].Ann Surg,1978; 187:183-188.
[53]Vijayan V, Shukla N, Johnson JL,et al. Long-term reduction of medial and intimal thickening in porcine saphenous vein grafts with a polyglactin biodegradable external sheath[J].J Vase Surg,2004; 40(5):1011-1019.
[54]Kontio R, Ruuttila P, Lindroos L, et al.Biodegradable polydioxanone and poly(l/d)lactide implants:an experimental study on peri- implant tissue response[J]. Int J Oral Maxillofac Surg,2005; 34(7):766-776.
[55]余咏潮,赵学维,徐志飞等.血管内皮生长因子在血管外支架预防移植静脉再狭窄中的作用[J].第二军医大学学报,2009;30(5)：509-512.
[56]潘文标,郑家豪,连锋等,血管外支架预防静脉桥再狭窄的实验研究[J].上海交通大学学报(医学版),2006；26(10),1150-1153.
[57]Mehta D, George SJ, Jeremy JY, et al.External stenting reduces long-term medial and neointimal thickening and platelet derived grow factor expression in a pig model of arteriovenous bypass grafting[J]. Nature Med,1998; 4(2):235-239.
[58]Sterpetti AV, Cucina A, Randone B, et al. Growth factor production by arterial and vein grafts:relevance to coronary artery bypass grafting[J]. Surgery,1996; 120(3):460-467.
[59]周俊,赵学维,徐志飞等.外支架通透性对移植血管再狭窄的影响[J],第四军医大学学报,2008；29(18)：1692-1695.
[60]段亮,肖明第,游庆军等.大孔隙非限制性血管外支架抑制移植静脉内膜增生的实验研究[J].中国胸心血管外科临床杂志,2007；14(5)：358-361.
[61]George SJ, Izzat MB, Gadsdon P, et al. Macro porosity is necessary for the reduction of neointimal and medial thickening by external stenting of porcine saphenous vein bypass grafts[J].Atherosclerosis,2001; 155:329-336.
[62]Goronzy JJ, Weyand CM. Cytokines in giant cell arteritis[J]. Cleve Clin J Med,2002; 69:91-94.
[63]Weyand CM, Goronzy JJ. Pathogenic mechanisms in giant cell arteritis [J]. Cleve Clin J Med,2002; 69:28-32.
[64][64]Hinrichs WL, Zweep HP, Satoh S, et al. Supporting, mircroporous, elastomeric, degradable prostheses to improve the arterialization of autologous vein grafts [J]. Biomaterials,1994; 15(2):83-91.
[65]Vijayan V, Shukla N, Johnson JL, et al. Long-term reduction of medial and intimal thickening in porcine saphenous vein grafts with a polyglactin biodegradable external sheath[J]. Vasc Surg,2004; 40(5):1011-1019.
[66]Jeremy JY, Bulbulia R, Johnson JL, et al. A bioabsorbable(polyglactin), nonrestrictive, external sheath inhibits porcine saphenous vein graft thickening [J].J Thorac Cardiovasc Surg,2004; 127(6):1766-1772.
[67]Krejca M, Skarysz J, Szmagala P, et al. A new outside stent-does it prevent vein graft intimal proliferation[J]? Eur J Cardiothorac Surg,2002; 22(12):898-903.
[68]Weinberger J, Simon AD. Intracoronary irradiation for the Prevention of restenosis[J].Curr OPinCardiol,1997; 12(5):468-474.
[69]Verin V, Popowski Y, Bruyne B, et al. Endoluminal beta-radiationtherapy for the prevention of coronary restenosis after balloon angioplasty[J].N Engl J Med,2001; 344(4):243-249.
[70]胡涛,贾国良,王海吕等.低频电磁场对大鼠主动脉平滑肌细胞骨桥蛋白基因表达的影响[J].中华物理医学与康复杂志,2006；28(2)：91-94.
[71]Tepe G, Dinkelborg LM, Brehme U, et al. Prophylaxis of restenosis with (186)re-labeled stents in a rabbit model[J].Circulation,2001; 104(4):480-485.
[72]Kipshidze N, Keelan MH, Petersen JR, et al. Photoactivation of vascular iNOS and elevation of cGMP in vivo:possible mechanism for Photovasorelaxation and inhibition of restenosis in an atherosclerotic rabbit models[J]. Photochem Photobiol,2000; 72(4):579-582.
[73]顾瑛,刘凡光,江忆平等.510.6nm激光诱导兔在体血管平滑肌细胞凋亡的研究[J].中国激光医学杂志,1999；8(3)：141-144.
[74]Mansfield R,Bown S.McEwan J.Photodynamic therapy:shedding light on restenosis [J].Heart,2001; 86(6):612-618.
[75]Krammer B.Vascular effects of photodynamic therapy. Anticancer Res.2001 21(6B):4271-4277.
[76]OverhausM, Heckenkamp JKossodo S, et al.photodynamic therapy generates a matrix barrier to invasive vaseular cell migration[J].Cire Res,2000; 86:334-340.
[77]Peter R, Watennan MO, Joerg H, et al. Mechanisms of reduced human fascular cell migration after Photodynamic therapy[J]. Photochemistry and Photobiology,2002; 46-50.
[78]Wyllie AH.Apoptosis:anoverview[J]. Br Med Bull,1997; 53:451-465.
[79]Statius van Eps RG, Mark LL, schiereck J, et al. photodynamic therapy inhibits the injury-induced fibrotic response of vascular smooth muscle cells[J]. Eur J Vase Endovasc Surg,1999; 18:417-423.
[80]Chanda J, Kuribayashi R, LiU KX, et al. Inhibitory effect of photooxidation on intimal and medial thickening of saphenous vein[J]. Ann Thorac Surg,1998; 66(2),449-454.
[81]Liu KX, Yamamoto F,Sekine S, et al.Inhibitory effect of methylene blue-induced Photooxidation on intimal thickening of vein graft[J].AnnThorac Surg,1999; 68(1):84-88.
[82]Statius RG, Mark LL, LaMuraglia GM. photodynamic therapy inhibits the injury-induced fibrotic response of vascular smooth muscle cells[J].Eur J Vase Endovasc Surg,1999; 18(5):417-423.
[83]Adili F, Statius van Eps R, Karp S, et al. Differential modulation of vascular endothelial and smooth muscle cell function by photodynamic therapy of extracellular matrix:novel insights into radical-mediated prevention of intimal hyperplasia[J]. J Vasc Surg,1996; 23:698-705.
[84]Statius van Eps RG, LaMuraglia GM. Photodynamic therapy inhibits transforming growth factor β activity associated with vascular smooth muscle cell injury [J].J Vase Surg,1997; 25:1044-1053.
[85]Hemant S. Thatte and Shukri F. Khun. The coronary artery bypass conduit:Intraoperative endothelial injury and its implication on graft pateney[J]. Ann Thorae Surg,2001; 72:2245S-2252S.
[86]Jeffrey H. Shuhaiber, Alexander N, et al.Mechanisms and future directions for Prevention of vein graft failure Incoronary bypass surgery[J]. Eur J Cardio Thorac Surg,2002; 22:387-396.
[87]刘培生,陈鑫,徐明等.不同扩张液在冠状动脉旁路移植术中对大隐静脉内皮细胞保护的对比研究[J].南京医科大学学报,2004；24：140-143.
[88]Jefrey HS, Alexander NE, Malek GM,et al. Mechanisms and future directions for prevention of vein graft failure in coronary bypass surgery[J].Eur J Cardio-Thorac Surgery,2002; 22:387-396.
[89]李寒,陈建明,张载高等.改良扩张方法对兔静脉移植物内皮细胞保护作用研究[J].心肺血管病杂志,2007；26(4),221-223.
[90]Vural KM, Oz MC, Liao H, et al. Membrane stabilization in harvested vein graft storage: effects on adhesion molecule expression and nitric oxide syntheisis[J]. Eur J Cardio Surgery,1999; 16:150-155.
[2]Asahara T, Masuda H, Takahashi T, et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization[J].Circ Res,1999; 85(3):221-228.
[3]Planat-Benard V, Silvestre JS, Cousin B, et al. Plasticity of human adipose lineage cells towards endothelial cells:physiological and therapeutic perspective [J].Circulation,2004; 109(5):656-663.
[4]Hristov M, Erl W, Weber PC. Endothelial progenitor cells:mobilization, differentiation and homin [J]. Arterioscler Thromb Vase Biol,2003; 23(7):1185-1189.
[5]Hu Y, Zhang Y, Torsney E, et al. Abundant progenitor cells in the adventitia contribute to atherosclerosis of vein grafts in ApoE-deficient mice[J]J Clin Invest,2004 113(9):1249-1251.
[6]Planat-Banard V, Silvestre JS, Cousin B, et al. Plasticity of Adipose tissue:a promising therapeutic avenue in the treatment of cardiovascular and blood diseases? [J].Arch Mai CoeurVaiss,2005; 98(9):922-926.
[7]Arsic N, Mamaeva D, Lamb NJ, et al. Muscle-derived stem cells isolated as non-adherent population give rise to cardiac, skeletal muscle and neural lineages[J]. Exp Cell Res,2008; 314(6):1266-1280.
[8]Murohara T, Ikeda H, Duan J. Transplanted cord blood-derived endothelial progenitor cells augment postnatal neovascularization[J] J Clin Invest,2000,105(11):1527-1536.
[9]马良龙,黄惠民,蒋祖明,俞晓青,邹文艳.内皮祖细胞定向分化平滑肌细胞的实验研究[J].上海交通大学学报(医学版),2006；18(8)：55-58.
[10]张军霞,尤永平,傅震等.内皮祖细胞与胶质瘤关系的研究进展[J].医学研究生学报,2007,20(1)：94-96.
[11]Rafii S, Lyden D, Benezra R, et al. Vascular and hematopoietic stem cells:novel targets for anti-angiogenesis therapy? [J].Nat Rev Cancer,2002; 2(11):826-835.
[12]Miraqlia S, Godfrey W, Yin AH, et a1. A novel five-transmembrane hematopoietic stem cell antigen:isolation, characterization, and molecular cloning[J]. Blood,1997,90(12): 5013—5021.
[13]Corbeil D, Roper K, Hellwiq B, et a 1. The human AC133 hematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions[J]. J Biol Chem,2000,275(8):5512-5520.
[14]Hur J, Yoon CH, Kim HS, et al. Characterization of two types of Endothelial progenitor cells and their different contribution to neovasculogenesis[J]. Arterioscler Thromb Vase Biol,2004,24(2):288-293.
[15]Rookmaaker MB, Verqeer M, van Zonneveld AJ, et al. Endothelial progenitor cells:mainly derived from the monocyte/macrophage-containing C D34-mononuclear cell population and only in part from the hematopoietic stem cell-containing CD34+ mononuclear cell population[J]. Circulation 2003;107(8):1164-1169.
[16]Mancinelli F, Tamburini A, Spagnoli A, et al. Optimizing umbilical cord blood collection: impact of obstetric factors versus quality of cord blood units[J].Transplant Proc,2006, 38(4):1174-1176.
[17]Kaushal S, Amiel GE, Guleserian KJ, et al. Functional small-diameter neovessels created using endothelial progenitor cells expanded ex vivo[J]. Nat Med,2001; 7(9):1035-1040.
[18]Schatteman GC, Hanlon HD, Jiao C, et al. Blood-derived angioblasts accelerate blood-flow restoration in diabetic mice[J].J Clin Invest,2000;106(4):571-578.
[19]D'Arena G, Savino L, Nunziata G, et al. Immunophenotypic profile of AC133-positive cells in bone marrow, mobilized peripheral blood and umbilical cord blood[J]. Leuk Lymphoma,2002; 43(4):869-873.
[20]Hur J, Yoon CH, Kim HS, et al. Characterization of two types of endothelial progenitor cells and their different contributions to neovasculogenesis. Arterioscler Thromb Vase Biol[J].2004;24(2):288-293.
[21]Brown MA, Wallace CS, Angelos M, et al. Characterization of umbilical cord blood-derived late outgrowth endothelial progenitor cells exposed to laminar shear stress[J].Tissue Engpart A,2009; 15(11):3575-3587.
[22]Rehman J, Li J, Orschell C, et al. Peripheral blood endothelial progenitor cells are derived from monocyte/macrophages and secrete angiogenic growth factors [J]. Circulation,2003, 107 (8):1164-1169.
[23]Kocher AA, schuscter MD, Szabolcs MJ, et al. Neovascularization,of ischemic myocardium by human bone marrow derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling, and improves cardiac function[J],Nat Med,2001,7:430-436.
[24]Kaushal S, Gilad EA, Krtsine JG, et al. Fuctional small-diameter neovessels created using endothelial progenitor cells expanded ex vivo[J].Nat Med,2001; 7(9):1035-1040.
[25]Rsfii S, Meeus S, Dias S, et al. Contribution of marrow—erived progenitors to vascular and cardiac regeneration[J] Semin Cell Dev Biol,2002,13(1):61-67.
[26]Hettori K, Heissig B, Wu Y, et al. Placental growth factor reconstitutes hematopoiesis by recuriting VEGFRI(+)stem ceils from bone—arrow microenvironment[J]. Nat Med, 2002,8(8):841—849.
[27]Murayama T, Tepper OM, Silver M, et al. Determination of bone marrow-derived endothelial progenitor cell significance in angiogenic growth factor-induced neovascul arization in vivo[J]. Exp Hematol,2002,30(8):967-972.
[28]Walter DH, Rittig K, Bahlmann FH, et al. Statin therapy accelerates reendothelialization: a hovel effect involving mobilization and incorporation of bone marrow derived endothelial progenitor cells [J]. Circulation,2002,105(25):3017-3024.
[29]Badorf C, Brandes RP, Popp R, et al.Transdifferentiation of blood-derived human adult endothelial progenitor cells into functionally active cardiomyocytes[J].Circulation 2003: 107(7):1024-1032.
[30]Verama S, Kuliszewski MA, Li SH, et al. C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and runetion[J]. Circulation,2004; 109(17): 2058-2067.
[31]Stefanec T. Endothelial apoptosis:could it have a role in the pathogenesis and reatment of disease? [J]. Chest,2000; 117(3):841-854.
[32]Cosentino F, Luscher TF. Endothelial dysfunction in diabetes mellitus [J]. J Cardio Vase Phar mocol,1998; 32(Supp13):s54-s56.
[33]Wang Y, Dong Y, Li R, et al. Transmyocardial revascularization and vascular endothelial growth factor administration enhance effect of cell transplantation for myocardial infarct repair in rats[J].Coron Artery Dis,2006; 17(3):275-281.
[34]Aicher A, Zeiher AM, Dimmelerm S, et al. Mobilizing endothelial progenitor cells[J].Hypertension,2005; 45 (3):321-325.
[35]Kaushal S, Gilad EA, Krtsine JG, et al. Fuctional small-diameter neovessels created using endothelialprogenitor cells expanded ex vivo[J].Nat Med,2001; 7(9):1035-1040.
[36]Matsuo Y, Imanishi T, Hayashi Y, et al. The effect of endothelial progenitor cells on the development of collateral formation in patients with coronary artery disease[J]. Intern Med.2008; 47(3):127-134
[37]Masuda H, kalka C, Takahashi T, et al. Estrogen-mediated endothelial progenitor cell biology and kinetics for physiological postnatal vasculogenisis[J].Circ Res,2007; 101(6):598-606.
[38]Gill M, Dias S, Hattori K, et al. Vascular trauma induces rapid but transient mobilization of VEGFR2+ AC 133+ endothelial precursor cells[J],Cir Res,2001,88(2):167-174.
[39]Heissig B, Hattori K, Dias S, et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand[J]. Cell,2002; 109(5):625-637.
[40]Satoshi S, Toyoaki M. Mobilization of endothelial progenitor cells in patients with acute myocardial infarction[J]. Circulation,2001; 103(23):2776-2779.
[41]干莎莉,李静,王亚平等,人参皂甙诱导骨髓巨噬细胞表达造血生长因子的研究[J].解剖学报,2003；34(5)：500-505.
[1]Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis[J].Science,1997;275(5302):964-967.
[2]Asahara T, Masuda H, Takahashi T, et al. Bone marr ow origin of endothelial progenitor cells res ponsible for postnatal vasculogenesis in physiol ogical and pathological neovascularization[J].Circ Res,1999,85(3):2212-2228.
[3]Planat B V, Silvestre JS, Cousin B, et al.Plasticity of human adipose lineage cells towards endothelial cells:physiological and therapeutic perspective [J].Circulation,2004,109(5): 6562-6663.
[4]HristovM, ErlW, Weber PC. Endothelial progenitor cells:mobilization, differentiation and homing [J].Arteri oscler Thromb Vase Biol,2003,23(7):1185-1189.
[5]Hu Y, Zhang Y, Torsney,et al. Abundant progenitor cells in the adventitia contribute to atherosclerosis of vein grafts in ApoE2 deficient mice[J].J Clin Invest,2004,113(9): 1258-1265.
[6]Planat-Banard V,Silvestre JS,Cousin B,et al.Plasticity of Human Adipose Lineage cells towards endothelial cells plysiological and therapeutic perspectivers[J].Circulationg,2004, 109:656-663.
[7]Arsic N, Mamaeva D, Lamb NJ, et al. Muscle-derived stem cells isolated as non-adherent population give rise to cardiac, skeletal muscle and neural lineages[J]. Exp Cell Res,2008, 314(6):1266-1280.
[8]Murohara T, Ikeda H, Duan J. Transplanted cord blood2 derived endothelial progenitor cells augment postnatal neovascularization[J].J Clin Invest,2000,105(11):1527-1536.
[9]马良龙,黄惠民,蒋祖明,俞晓青,邹文艳.内皮祖细胞定向分化平滑肌细胞的实验研究[J]上海交通大学学报(医学版),2006；18(8)：55-58.
[10]张军霞,尤永平,傅震等.内皮祖细胞与胶质瘤关系的研究进展[J].医学研究生学报,,2007,20(1)：94-96.
[11]Rafii S, Lyden D, Benezra R, et al. Vascular and hematopoietic stem cells:novel targets for anti-angiogenesis therapy? [J].Nat Rev Cancer,2002,2(11):826-835.
[12]Holyoake TL. Alcom MJ. CD34+positive haemopoietic cells:biology and clinical applications[J]. Blood Rev,1994,8(2):113-124.
[13]Miraglia S, Godfrey W, Yin AH, et al. A A novel five-transmembrane hematopoietic stem cell antigen:isolation,characterization,and molecular cloning[J]. Blood,1997,90(12): 5013-5021.
[14]Corbeil D, Roper K,Hellwig et al. The human AC133 hematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions[J]. J Biol Chem,2000,275(8):5512-5520.
[15]Jin H, Chang2Hwan Y, Hyo2Soo K, et al. Characterization of two types of Endothelial p rogenitor cells and their different contribution to neovasculogenesis[J]. Arterioscler Thromb Vase Biol,2004; 24(2):288-293.
[16]Rookm aaker M B,Vergeer M,van Zonneveld AJ,et al.Endothelial progenitor cells:m ainly derived from themonocytem acrophage-containing CD 34 mononuclear cell population and only in part from the hem atopoietic stem cell-containing CD34+ mononuclear cell population[J]. Circulation 2003;108(21):el50.
[17]Mancinelli F, Tamburini A, Spagnoli A, et al. Optimizing um-bilical cord blood collection: impact of obstetric factors versus quality of cord blood units[J].Transplant Proc,2006,38(4): 1174-1176.
[18]Kaushal S, Gilad EA, Krtsine JG,et al. Fuctional small-diameter neovessels created using endothelialprogenitor cells expanded ex vivo[J].Nat Med,2001; 7(9):1035-1040.
[19]Schattem an G C,H anlon H D,Jiao C,et al.Blood-derived angioblasts accelerate blood-flow restoration in diabeticmice[J]. J C lin Invest2000;106(4):571-578.
[20]Arena G, Savino L, Nunziata G, et al. Immunophenotypic profile of AC133-positive cells in bone marrow,mobilized rleripheral blood and umbilical cord blood. Leuk Lymphoma,2002,43(4):869-873.
[21]J in H, Chang2Hwan Y, Hyo2Soo K, et al. Characterization of two types of Endothelial progenitor cells and their different contribution to neovasculogenesis [J]. Arterioscler Thromb Vasc Biol,2004,24(2):288-293.
[22]Hur J, Yoon CH, Kim HS, et al. Characterization of two types of endothelial progenitor cells and their different contributions to neovasculogenesis [J]. Arterioscler Thromb Vase Biol,2004;24(2):288-293.
[23]Rehman J,Li J,Orschell C,et al,Peripheral blood endothelial progenitor cells are derived from monocyte/macrophages and secrete angiogenic growth factors [J].circulation,2003, 107:1164-1169.
[24]Kocher AA,schuscter MD,Szabolcs MJ,et al,Neovascularization,of ischemic myocardium by human bone marrow derived angioblasts prevents cardiomyocyte apoptosis,reduces remodeling,and improves cardiac function [J].Nat Med,2001,7:430-436.
[25]Kaushal S, Gilad EA, Krtsine JG,et al. Fuctional small-diameter neovessels created using endothelialprogenitor cells expanded ex vivo[J]. Nat Med,2001; 7(9):1035-1040.
[26]Rsfii S, Meeus S, Dias S, et a 1. Contribution of marrow—erived progenitors to vascular and cardiac regeneration [J].Semin Cell Dev Biol,2002; 13(1):61-67.
[27]Hettori K, Heissig B, Wu Y, et al. Placental growth factor reconstitutes hematopoiesis by recuriting VEGFRI(+)stem ceils from bone-marrow microenvironment[J]. Nat Med,2002; 8(8):841-849.
[28]Murayama T, Tepper OM, Silver M, et al. Determination of bone marrow—erived endothelial progenitor cell significance in angiogenic growth factor-induced neovasculari-zation in vivo[J]. Exp Hematol,2002; 30(8):967-972.
[29]Walter DH, Rittig K, Bahlmann FH, et al. Statin therapy accelerates reendothelialization: a hovel effect involving mobilization and incorporation of bone marrow derived endothelial progenitor cells [J]. Circulation,2002; 105(25):3017-3024.
[30]Badorf C, Brandes RP, Popp R, et al.Transdifferentiation of blood-derived human adult endothel ial progeni tor cells into functionally active cardiomyocytes[J]. Circulation, 2003; 107(7):1024-1032.
[31]Verama S, Kuliszewski MA, Li SH, et al. C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and runetion[J]. Circulation,2004; 109(17): 2058-2067.
[32]Stefanec T. Endothelial apoptosis:could it have a role in the pathogenesis and reatment of disease[J]? Chest,2000; 117(3):841-854.
[33]Cosentino F,Luscher TF. Endothelial dysfunction in diabetes mellitus [J]. J Cardio Vase Pharmocol,1998; 32(Suppl3):s54-s56.
[34]Wang Y, Dong Y, Li R, et al.Transmyocardial revascularization and vascular endothelial growth factor administration enhance effect of cell transplantation for myocardial infarct repair in rats[J].Coron Artery Dis,2006; 17(3):275-281.
[35]Aicher A,Zeiher AM,Dimmelerm S,et al,Mobilizing endothelial progenitor cells[J]. Hypertension 2005; 45(3):321-325.
[36]Kaushal S, Gilad EA, Krtsine JG,et al. Fuctional small-diameter neovessels created using endothelialprogenitor cells expanded ex vivo[J]. Nat Med,2001; 7(9):1035-1040.
[37]Matsuo Y, Imanishi T, Hayashi Y, et al. The effect of endothelial progenitor cells on the development of collateral formation in patients with coronary artery disease[J]. Int Med. 2008; 47(3):127-134.
[38]Masuda H,kalka C,Takahashi T,et al,Estrogen-mediated endothelial progenitor cell biology and kinetics for physiological postnatal vasculogenisis[J]. Circ Res,2007 101(6):598-606.
[39][39]Muhammad G,Sergio D,Koichi H,et al,Vasculartrauma induces rapid but transcient mobilization of VEGFR2+ AC133+ endothelial precursor cells[J].Cir Res,2001; 88(2):167-174.
[40]Heissig B,Hattori K,Dias S,et al,Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand[J]. Cell,2002; 109(5):625-637.
[41]Satoshi S,Toyoaki M,Mobilization of endothelial progenitor cells in patients with acute myocardial infarction[J]. circulation,2001; 103(23):2776-2779.
[42]Werner N, Kosiol S, Schiegl T, et al. Circulating endothelial progenitor cells and cardiovascular outcomes[J]. N Engl J Med,2005; 353(10):999-1007.
[43]Matsuo Y, I manishi T, Hayashi Y, et al. The effect of senescence of endothelial p rogenit or cells on instent restenosis in patients undergoing coronary stenting [J].Int Med,2006; 45(9):581-587.
[44]Gerhar dM, Roddy MA, Greager SJ, et al. Ageing progressively impairs endothelium- dependent vascdilation in forearm resistance vessels of human[J].Human,1996:27(4): 849-853.
[45]Cosentino F, Luscher TF. Endothelial dysfunction in diabetes mellitus [J]. J Cardio Vase Phar mocol,1998; 32(Supp13):s54-s56.
[46]Wang Y, Dong Y, Li R, et al. Transmyocardial revascularization and vascular endothelial growth factor administration enhance effect of cell trans p lantati on for myocardial infarct repair in rats[J]. Coron Artery Dis,2006; 17(3):275-281.
[47]Lowe HC, Oesterle S N, Khachigian LM. Coronary in stent restenosis:Current status and future strategies[J]. J Am Coll Cardiol,2002; 39(2):183-193.
[48]Yoon YS, Lee N, Scadova H. Myocardial regenerati on with bone marrow derived stem cells [J]. Biol Cell,2005; 97(4):253-263.
[49]张威,周莉,金惠铭等.用CD133免疫磁珠分离脐血内皮祖细胞的实验研究[J].中国病理生理杂志,2005；21(9)：1675-1680.
[50]Jacob G, Itzhak H, Emil G, et al. Number and adhesive properties of circulating endothelial progenitor cells in'patients within stent restenosis [J]. Arteri oscler Thromb Vase Biol, 2003: 23(12):e52-e60.
[51]Okazaki T, Ebihara S, Asada M,et al. Granulocyte colony stimulating factor promotes tumor angiogenes is via increasing circulating endothelial progenitor cells and Grl+CD11b+cells in cancer animal models[J]. Int Immunol 2006; 18(1):1-9.
[52]肖海波.转染VEGF基因的内皮祖细胞移植丁缺血心肌的试验研究[D].第二军医大学博士学位论文,2004.
[53]Schachinger V, Assmus B, Britten MB, et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction:final one-year results of the TOPCARE-AMI Trial[J].J Am Coll Cardiol,2004; 44(8):1690-1699.
[54]Okazaki T, Ebihara S, Asada M, et al. Granulocyte colony-stimulating factor promotes rumor angiogenes is via increasing circulating endothelial progenitor cells and Grl+CD11b+ cells in cancer animal models[J]. Int Immunol 2006; 18(1):1-9.
[55]Asahara T,Murasawa S. Endothelial progenitor cells for Vasculogenesis [J]. Physiology, 2005:20(2):36-42.
[56]Zeng L, Xiao Q, Margariti A, et al. HDAC3 is crucial in shear and VEGF-induced stem cell differentiation toward endothelia cells[J].Cell Biol,2006; 174(7):1059-1069.
[57]Erik BF, Katrin W. CD34-/CD133+/VEGFR-2+ Endothelial Progenitor Cell Subpopulation With Potent Vasoregenerative Capacities[J].Circ Res 2006:98(3):20-25.
[58]Gries e DP, Ehsan A, Luis G,et al.Isolation and Transplantation of Autologous Circulating Endothelial Cells into denuded vessels and prosthetic grafts:Implications for Cell-Based Vascular Therapy[J].Circulation,2003; 108(21):2710-2715.
[59]Asahara T, Takahashi T, Masuda H, et al. VEGF contribute to postnatal neovascularization by mobilizing bone marrow derived endothelial progenitor cells[J]. EMBO,1999; 18(14): 3964-3972.
[60]Rabatti D. The involvement of endothelial progenitor cells in tumor angiogenesis [J]. J Cell Mol Med,2004; 8(3):294-300.
[61]Aicher A, Zeiher AM, Dimmelerm S, et al. Mobilizing endothelial progenitor cells[J]. Hypertension,2005; 45 (3):321-325.
[1]Brener SJ,Lytle B, Casserly IP, et al.Propensity analysis of long-term survival after surgical or percutaneous revascularization in patients with multivessel coronary artery disease and high-risk features[J]. Circulation,2004,109(19):2290-2295.
[2]Aear C, Jevara VA, Portoghese M, et al. Revival of the radial artery For coronary artery bypass grafting[J]. Ann Thorac Surg,1992,54:652-659.
[3]Grondin CM, Campeau L, Lesperanee J, et al. Atherosel erotic changes in coronary vein grafts 6 years after operation:angiographie aspect in 110 patients[J].J Thoac Cardiovasc Surg,1979,77:24-31.
[4]Weintraub WS, Jones EL, Carver JM. Frequency of repeat coronary bypass or coronary angioplasty after coronary artery bypass surgery using saphenous venous grafts[J]. Am J Cardiol,1994,73:103-112.
[5]何飞,孙明等。通脉汤对损伤的血管内皮细胞NO生成及纤溶平衡的影响[J].J China Physician,2004,6(1):66-69.
[6]Favaloro RG. Landmarks in the development of coronary artery bypass surgery[J], Circulation.1998,98(5):466-478.
[7]Canver CC, Conduit options in coronary artery bypass[J].Surgery Chest.1995,108: 1150-1155.
[8]Eagle KA.Guyton RA,Davidoff R,et al.ACC/AHA guidelines for coronary artery bypass graft surgery:executive summary and recommendations:A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines(Committee to revise the 1991 guidelines for coronary artery bypass graft surgery [J]. Circulation,1999, 100(13):1464-1480.
[9]Tian XD, Zhou NK, Li BJ, et al.Effects and mechanisms of non-restrictive external stent for prevention of vein graft restenosis in a rabbit model. Chin Med J。 2010; 123(17):2400-2404.
[10]Handa M, Li W, Morioka K, et al.Adventitial delivery of platelet-derived endothelial cell growth factor gene prevented intimal hyperplasia of vein graft. J Vase Surg.2008 Dec;48(6):1566-1574.
[11]Domingos S.R. Souza, Michael R. Dashwood, Janice C.S. Tsui, et al.ImProved Patency in vein grafts harvested with surrounding tissue:results of a randomized study using three harvesting techniques. Ann Thorac Surg,2002,73:1189-1195.
[12]Del Rizzo DF, Moon MC, Werner JP, et al. A novel organ culture method to study intimal hyperplasia at the site of a coronary artery bypass anastomosis.Ann Thorac Surg. 2001:71:1273-1280.
[13]Miketic S, Carlsson J, Tebbe U. Influence of gradually increased slow balloon inflation on restenosis after coronary angioplasty. Am Heart J 1998 Apr:135(4):709-713.
[14]Zhang L,Ma Y,Zhang J,et al.A new cellular signaling mechanism for angiotensin Ⅱ activation of NF-kappaB:An IkappaB-independent, RSK-mediated phosphorylation of p65[J].Arterioscler Thromb Vase Biol,2005,25(6):1148-1153.
[15]Lopes RD,Hafley GE,Allen KB,et al.Endoscopic versus open vein-graft harvesting in coronary-artery bypass surgery[J].N Engl JMed,2009,361(3):235-244.
[16]Ellis,SG,Chen MS,Jia G,et al.Relation of polymorphisms in five genes to long-term aortocoronary saphenous vein graft patency[J].Am J Cardiol 2007,99(8):1087-1089.
[17]肖明第,尤文俊,袁忠祥等,冠状动脉旁路移植术后影响静脉移植物内膜增生因素的实验研究[J].中华医学杂志,2002,82(22)：1550-1552.
[18]Joseph G, Motwani and Eric J. Topol. Aortocoronary Saphenous vein graft disease: Pathogenesis, Predisposition, and Prevention[J]. Circulation,1998,97:916-931.
[19]Hemant S,Thatte and ShukriF. Khuri.The coronary artery bypass conduit:1. Intraoperative endothelial injury and its implication on graft patency. Ann Thorac Surg,2001, 72:2245S-2252S.
[20]Jeffrey H. Shuhaiber, Alexander N. Evans, Malek G. Massad*.et al·Mechanisms and future directions for prevention of vein graft failure in coronary bypass surgery. European Journal of Cardio-thoracic Surgery 2002,22:387-396.
[21]hafi S, Palinski W, Born GVR. Comparison of uptake and degradation of low density lipoproteins by arteries and veins of rabbits[J]. Atherosclerosis,1987,66:131-138.
[22]Gracia RL, Coltrera, Gown AM. Analsis of proliferative grade using anti-PCNA monoclonal antibodies in fixed, embedded tissue.Ann J Pathol.1989;134:733-739.
[23]Speir E, Epstein SE.Inhibition of smooth muscle cell proliferation by an antisense oligodeoxynueleotide targeting the message rRNA encoding prolifering cell nuelear antigen[J]. Circulation,1992,86:538-544.
[24]Alan Fine, Ronald H.Goldstein.The effect of TGF — beta on cell proliferation and collagen formation by lung fibroblasts. J BioChem.1987;262(8):3897-3902.
[25]Clardio KuPfahl, Daniel Pink, Katharina Friedrich, et al.angiotensin Ⅱ directly increases transforming grovth factorβl and osteopontin and indirectly affects collagen mRNA expression in the human heart.Cardiovasc Res.2000;46:463-475.
[26]William Durante, Lan Liao, Sylvia V, et al.Transforming growth factor-betal Stimulates L-arginine transport and metabolism in vascular smooth muscle cells.Cireulation2001;103: 1121-1127.
[27]Siow R C, Mallawarachchi C M,Weissberg PL. Migration of adventitial myofibroblasts following vascular ballooninjury:insights from in vivo gene transferto rat carotid arteries [J]. Cardiovasc Res,2003,59(1):212-221.
[28]Tashiro H, Shimokawa H, Sadamatn K, etal. Prognostic significance of plasmaconcentra-tions of transforming growthfactor-beta 1 in patients with coronaryartery disease[J]. Coron Artery Dis,2002,13(3):139-143.
[29]Hao J,Ju H,Zhao S,et al. Elevation of expression of Smads 2,3 and 4, decorin and TGF-β in the chronic phase of myocardial infarct scar healing [J].J Mol Cell Cardio,1999,31(3): 667-678.
[30]Smith J D,Bryant S R,Couper L L,et al. Soluble transforming growth factor-beta type Ⅱ receptor inhibits negative remodeling, fibroblast transdifferentiation, and intimal lesion formation but not endothelial growth[J]. Cir Res,1999,84(10)1212-1222.
[31]Lindner V.vascular repair process is mediated by transforminggrowth factorbeta[J]. Z Kardiol,2001,90(Suppl 3):17-22.
[32]Toprak V, Sirin BH, Tok D, et alThe effect of cardiopulmonary bypass on the expression of inducible nitric oxide synthase, endothelial nitric oxide synthase, and vascular endothelial growth factor in the internal mammary artery[J].J Cardiothorac Vase Anesth.2006;20(1): 63-67.
[33]郑家豪,镡朝晖,穆军升等,eNOS基因转染预防静脉移植血管再狭窄[J]. 中国心胸血管外科临床杂志,2003,10(2)：81-84.
[34]Luttun A, Carmeliet G,Canneliet P.Vascular progenitors:from biology to treatment[J]. Trends Cardiovasc Med,2002,12:88-96.
[35]Shi Q, Rafii s,Wu MH,et al.Evidence for circulating bone marrow derived endothelial cells[J].Blood,1998,92:362-367.
[36]Werner N, Priller J, Laufs U. et al.Bone marrow-derived progenitor cells modulate vascular reendothelialization and neointimal formation:effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition. Arterioscler Thromb Vase Biol,2002,22:1567-1572.
[37]Luseher TF, Barton M.Biology of the endothelium. ClinCardiol,1997,20(11 suppl 2):3-10.
[38]Miller Kasprzak E, Jagodzinski PP. Endothelial progenitor cells as a new agent contributing to vascular repair. Arch Immunol Ther Exp (Warsz).2007 Jul-Aug; 55(4):247-59.
[39]Loomans CJM, de Koening EJP, Stal FJT, et al. Endothelial progenitor cell dysfunction. A novel concept in the pathogenesis of vascular complications of type I diabetes.Diabetes.2004,53:195-199.
[40]Strehlow K,Werner N, Berweiler J, t al. Estrogen increases bone marrow-derived endothelial progenitor cell production and diminishes neointima formation. Circulation.2003; 107(24):3059-3065.
[41]Thum T, Fraccarollo D, Schultheiss M. et al. Endothelial nitric oxide synthase uncoupling impairs endothelial progenitor cell mobilization and function in diabetes.Diabetes.2007; 56(3):666-74.
[42]王莎莉,李静,王亚平等,人参包甙诱导骨髓巨噬细胞表达造血生长因子的研究[J].解剖学报,2003,34(5)：500-505.
[43]谢薇,夏凌辉,方峻等,人参皂苷Rb1对人脐静脉内皮细胞一氧化氮释放和TGF-β1表达的影响和意义[J］.中国医院药学杂志,2007,27(9)：1225-1228.
[1]Brener SJ,Lytle B,Casserly IP,et al. Propensity analysis of long-term survival after surgical or percutaneous revascularization in patients with multivessel coronary artery disease and high-risk features[J]. Circulation,2004; 109(19):2290-2295.
[2]Eagle KA, Guyton RA,Davidoff R,et al.ACC/AHA guidelines for coronary artery bypass graft surgery:executive summary and recommendations:A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines(Committee to revise the 1991 guidelines for coronary artery bypass graft surgery[J].Circulation,1999; 100(13):1464-1480.
[3]Domingos S.R, Souza, Michael R, et al.Improved Patency in vein grafts harvested with surrounding tissue:results of a randomized study using three harvesting techniques[J]. Ann Thorac Surg,2002; 73:1189-1195.
[4]潘文标,郑家豪,连锋等.静脉桥狭窄实验动物模型的建立[J].现代医学,2006；34(1)：6-8.
[5]Qiao A, Zeng Y, Xu X. Comparisons of hemodynamics in 1-way and 2-way CABG[J].J Biomed Eng,2006; 23(2):295-299.
[6]Verrier ED, Boyle EM Jr. Endothelial cell injury in cardiovascular surgery[J].Ann Thorac Surg,1996; 62:915-922.
[7]Nachman RL, Silverstein R.Hypercoagulable state[J]s. Ann Intern Med,1993; 119:819-827.
[8]Eric Allaire, Alexander W, Clowes. Endothelial cell Injury in Cardiovascular Surgery:The Intimal Hyperplastic Response[J]. Ann Thorae Surg,1997; 63:582-591.
[9]Zhang L,Ma Y,Zhang J,et al.A new cellular signaling mechanism for angiotensin Ⅱ activation of NF-kappaB:An IkappaB-independent, RSK-mediated phosphorylation of p65 [J]. Arterioscler Thromb Vase Biol,2005; 25(6):1148-1153.
[10]Lopes RD, Hafley GE, Allen KB, et al. Endoscopic versus open vein-graft harvesting in coronary-artery bypass surgery[J].N Engl J Med,2009; 361(3):235-244.
[II]Parang P, Arora R. Coronary vein graft disease:pathogenesis and prevention[J].Can J Cardio!,2009; 25(2):e57-62.
[12]Ellis SG, Chen MS, Jia G,et al.Relation of polymorphisms in five genes to long-term aortocoronary saphenous vein graft patency[J].Am J Cardiol 2007; 99(8):1087-1089.
[13]萧明第,尤文俊,袁忠祥等.冠状动脉旁路移植术后影响静脉移植物内膜增生因素的实验研究中华医学杂志,2002；82(22)：1550-1552.
[14]Durante W, Liao L, Reyna SV, et al. Transform in growth factor-β1 stimulates L-arginine transport and metabolism in vascular smooth muscle cells [J].Circulation,2001; 103(8):1121-1127.
[15]Joseph G, Motwani, Eric J, et al. Aortocoronary Saphenous vein graft disease: Pathogenesis, Predisposition, and Prevention[J]. Circulation.1998：97:916-931.
[16]Hemant S, Thatte, Shukri F. Khuri.The coronary artery bypass conduit:Intraoperative endothelial injury and its implication on graft patency[J]. Ann Thorac Surg,2001; 72:2245S-2252S.
[17]Jeffrey H, Shuhaiber, Alexander N，et al. Mechanisms and future directions for prevention of vein graft failure in coronary bypass surgery[J]. Eur J Cardio Thorac Surg,2002; 22:387-396.
[18]Hafi S, Palinski W, Born GVR. Comparison of uptake and degradation of low density lipoproteins by arteries and veins of rabbits[J]. Atherosclerosis,1987; 66:131-138.
[19]Larson RM, Hagen PO, Fuehs JCA. Lipid biosynthesis in arteries, veins and venous grafts[J].Circulation,1974; 50(supplIII):131-139.
[20]Stein PD, Dalen JE, Goldman S, et al. Antithrombotic therapy in patients with saphenous vein and internal mammary artery bypass grafts[J].Chest,1995; 108(4):424S-430S.
[21]Dacey LJ, Munoz JJ, Johnson ER, et al. Effect of preoperative aspirin use on mortality in coronary artery bypass grafting patients[J].Ann Thorac Surg,2000; 70(6):1986-1990.
[22]Stein PD, Dalen JE, Goldman S, et al. Antithrombotic therapy in patients with saphenous vein and internal mammary artery bypass grafts[J]. Chest 2001,119(SuppI.l):278S-282S.,
[23]王新文,张强,王斌.肝素对自体移植静脉内膜增殖的影响.中国实用外科杂志,1999；19(4)：230-231.
[24]Porter KE, Turner NA, Titus JL, et al. Statins for the prevention of vein graft stenosis:a role for inhibition of matrix metalloproteinase-9[J]. Biochem Soc Trans,2002; 30(2):120-126.
[25]Knatterud GL, Rosenberg Y, Campeau L,et al. Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial. Post CABG Investigators [J].Circulation,2000; 102(2):157-165.
[26]Frick M, Dulak J, Cisowski J，et al. Statins differentially regulate vascular endothelial growth factor synthesis in endothelial and vascular smooth muscle cells[J]. Atheros clerosis,2003; 170(2):229-236.
[27]Motayama K, Fukumoto S, Koyama H, et al. SREBP inhibits VEGF expression in human smooth muscle cells[J].Biochem Biophys Res Commun,2006; 342(1):354-360.
[28]Cucina A, Borrelli V, Randone B, et al. Vascular endothelial growth factor increases the migration and proliferation of smooth muscle cells through the mediation of growth factors released by endothelial cells [J]. J Surg Res,2003; 09(1):16-23.
[29]Manfred L, Marco C, Markus H, et al. ACE inhibitor and AT(1) antagonist blockade of deformation-induced gene expression in the rabbit jugular vein through beta(2) receptor activation[J]. Arterioscler Thromb VasC Biol, Dallas,2001; 61-66.
[30]Sullivan JM, El-Zeky F, Vander Zwaag R, et al. Effect on survival ofEstrogen replacement therapy after coronary artery bypass grafting[J].Am J Cardiol,1997; 79:847-850.
[31]Jeffrey H. Shuhaiber. Alexander N, et al. Mechanisms and future directions for prevention of vein graft failure in coronary bypass surgery[J]. Eur J Cardio Thorac Surg,2002; 22:387-396.
[32]Andrew F, Phillip F, Heller S, et al. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent[J].Circulation,2001; 104 (4):473-481.
[33]Stark VK, Hoch JR, Warner TF. Monocyte chemotactic protein-1 expression is associated with the development of vein graft intimal hyperplasia[J]. Arterioscler Thromb Vase Biol,1997; 17(8):1614-1621.
[34]郑家豪,镡朝晖,穆军升等.eNOS基因转染预防静脉移植血管再狭窄[J].中国心胸血管外科临床杂志,2003；10(2)：81-84.
[35]迟立群,李功宋,高长青等,野生型p53基因转染和低能量激光照射防治移植静脉再狭窄的实验研究[J].中华胸心血管外科杂志,2003；19(1)：50-52.
[36]George SJ, Angelini GD, Capogrossi MC, et al. Wild-type p53 gene transfer inhibits neointima fonnation in human saphenous vein by modulation of smooth muscle cell migration and induction of apoptosis [J].Gene Therapy,2001:8(9):668-676.
[37]Johnson JL, Van Eys GJ, Angelini GD, et al. Injury induces dedifferentiation of smooth muscle cells and increased matrix-degrading metalloproteinase activity in human saphenous vein[J].Arterioscler Thromb Vase Biol,2001; 21(7):1146-1151.
[38]Joseph G, Motwani and Erie J, Topol. Aortocoronary Saphenous vein Graft Disease: Pathogenesis, PredisPosition, and Prevention[J]. Circulation,1998; 97:916-931.
[39]Mary Beth Deyoung, David A.Diehek.Gene Therapy for Restenosis. Are We Ready[J] Circ Res,1998; 82:306-313.
[40]Luttun A, Carmeliet G,Canneliet P.Vascular progenitors:from biology to treatment[J],Trends Cardiovasc Med,2002,12:88-96.
[41]Wern N, Junk S, Laufs U, et al. Intravenous transfusion of endothelial Progenitor cells reduces neointima formation after vascular injury[J].Circ Res,2003; 93(2):e 17-e24.
[42]Fujiyama S, Amano K, Uehira K, et al. Bone marrow monocyte lineage cells adhere on injured endothelium in a monocyte chemoattractant Protein-l-dependent manner and accelerate reendothelialization as endothelial progenitor cells[J].Circ Res,2003: 93(10):980-989.
[43]Kaushal S, Amiel GE, Guleserian KJ, et al. Functional small-diameter neovessels created using endothelial Progenitor cells expanded ex vivo[J].Nat Med,2001; 7(9):1035-1040.
[44]Kong D, Melo LG, Mangi AA,et al. Enhanced inhibition of neointimal hyperplasia by genetically engineered endothelia Progenitor cells[J]. circulatron,2004; 109(14):1769-1775.
[45]Shi Q, Rafii s,Wu MH,et al.Evidence for circulating bone marrow derived endothelial cells[J].Blood,1998; 92:362-367.
[46]Werner N, Priller J, Laufs U, et al.Bone marrow-derived progenitor cells modulate vascular reendothelialization and neointimal formation:effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition[J].Arterioscler Thromb Vase Biol,2002,22:1567-1572.
[47]王立新,王奇,石海燕等.造血干细胞动员对移植静脉近期通畅率的影响[J].中囯胸心血管外科临床杂志,2007,14(1)：4l-45.
[48]王莎莉,李静,王亚平等.人参皂甙诱导骨髓巨噬细胞表达造血生长因子的研究[J].解剖学报,2003；34(5)：500-505.
[49]谢薇,夏凌辉,方峻等.人参皂茁Rb1对人脐静脉内皮细胞一氧化氮释放和TGF-β1表达的影响和意义[J].中国医院药学杂,2007；27(9)：1225-1228.
[50]Parsonnet V, Lari AA, Shah IH. New stent for support of veins in arterial grafts[J].Arch Surg,1963; 87(4):696-702.
[51]Liu SQ, Biomechancial basis of vascular tissue eng ineering[J].Crit Rev Biomed Eng,1999; 27(12):75-148.
[52]Karayannacos PE, Hosteller JR, Bond MG,et al. Late failure in vein grafts:mediating factors in subendothelial fibromuscular hyperplasia[J].Ann Surg,1978; 187:183-188.
[53]Vijayan V, Shukla N, Johnson JL,et al. Long-term reduction of medial and intimal thickening in porcine saphenous vein grafts with a polyglactin biodegradable external sheath[J].J Vase Surg,2004; 40(5):1011-1019.
[54]Kontio R, Ruuttila P, Lindroos L, et al.Biodegradable polydioxanone and poly(l/d)lactide implants:an experimental study on peri- implant tissue response[J]. Int J Oral Maxillofac Surg,2005; 34(7):766-776.
[55]余咏潮,赵学维,徐志飞等.血管内皮生长因子在血管外支架预防移植静脉再狭窄中的作用[J].第二军医大学学报,2009;30(5)：509-512.
[56]潘文标,郑家豪,连锋等,血管外支架预防静脉桥再狭窄的实验研究[J].上海交通大学学报(医学版),2006；26(10),1150-1153.
[57]Mehta D, George SJ, Jeremy JY, et al.External stenting reduces long-term medial and neointimal thickening and platelet derived grow factor expression in a pig model of arteriovenous bypass grafting[J]. Nature Med,1998; 4(2):235-239.
[58]Sterpetti AV, Cucina A, Randone B, et al. Growth factor production by arterial and vein grafts:relevance to coronary artery bypass grafting[J]. Surgery,1996; 120(3):460-467.
[59]周俊,赵学维,徐志飞等.外支架通透性对移植血管再狭窄的影响[J],第四军医大学学报,2008；29(18)：1692-1695.
[60]段亮,肖明第,游庆军等.大孔隙非限制性血管外支架抑制移植静脉内膜增生的实验研究[J].中国胸心血管外科临床杂志,2007；14(5)：358-361.
[61]George SJ, Izzat MB, Gadsdon P, et al. Macro porosity is necessary for the reduction of neointimal and medial thickening by external stenting of porcine saphenous vein bypass grafts[J].Atherosclerosis,2001; 155:329-336.
[62]Goronzy JJ, Weyand CM. Cytokines in giant cell arteritis[J]. Cleve Clin J Med,2002; 69:91-94.
[63]Weyand CM, Goronzy JJ. Pathogenic mechanisms in giant cell arteritis [J]. Cleve Clin J Med,2002; 69:28-32.
[64][64]Hinrichs WL, Zweep HP, Satoh S, et al. Supporting, mircroporous, elastomeric, degradable prostheses to improve the arterialization of autologous vein grafts [J]. Biomaterials,1994; 15(2):83-91.
[65]Vijayan V, Shukla N, Johnson JL, et al. Long-term reduction of medial and intimal thickening in porcine saphenous vein grafts with a polyglactin biodegradable external sheath[J]. Vasc Surg,2004; 40(5):1011-1019.
[66]Jeremy JY, Bulbulia R, Johnson JL, et al. A bioabsorbable(polyglactin), nonrestrictive, external sheath inhibits porcine saphenous vein graft thickening [J].J Thorac Cardiovasc Surg,2004; 127(6):1766-1772.
[67]Krejca M, Skarysz J, Szmagala P, et al. A new outside stent-does it prevent vein graft intimal proliferation[J]? Eur J Cardiothorac Surg,2002; 22(12):898-903.
[68]Weinberger J, Simon AD. Intracoronary irradiation for the Prevention of restenosis[J].Curr OPinCardiol,1997; 12(5):468-474.
[69]Verin V, Popowski Y, Bruyne B, et al. Endoluminal beta-radiationtherapy for the prevention of coronary restenosis after balloon angioplasty[J].N Engl J Med,2001; 344(4):243-249.
[70]胡涛,贾国良,王海吕等.低频电磁场对大鼠主动脉平滑肌细胞骨桥蛋白基因表达的影响[J].中华物理医学与康复杂志,2006；28(2)：91-94.
[71]Tepe G, Dinkelborg LM, Brehme U, et al. Prophylaxis of restenosis with (186)re-labeled stents in a rabbit model[J].Circulation,2001; 104(4):480-485.
[72]Kipshidze N, Keelan MH, Petersen JR, et al. Photoactivation of vascular iNOS and elevation of cGMP in vivo:possible mechanism for Photovasorelaxation and inhibition of restenosis in an atherosclerotic rabbit models[J]. Photochem Photobiol,2000; 72(4):579-582.
[73]顾瑛,刘凡光,江忆平等.510.6nm激光诱导兔在体血管平滑肌细胞凋亡的研究[J].中国激光医学杂志,1999；8(3)：141-144.
[74]Mansfield R,Bown S.McEwan J.Photodynamic therapy:shedding light on restenosis [J].Heart,2001; 86(6):612-618.
[75]Krammer B.Vascular effects of photodynamic therapy. Anticancer Res.2001 21(6B):4271-4277.
[76]OverhausM, Heckenkamp JKossodo S, et al.photodynamic therapy generates a matrix barrier to invasive vaseular cell migration[J].Cire Res,2000; 86:334-340.
[77]Peter R, Watennan MO, Joerg H, et al. Mechanisms of reduced human fascular cell migration after Photodynamic therapy[J]. Photochemistry and Photobiology,2002; 46-50.
[78]Wyllie AH.Apoptosis:anoverview[J]. Br Med Bull,1997; 53:451-465.
[79]Statius van Eps RG, Mark LL, schiereck J, et al. photodynamic therapy inhibits the injury-induced fibrotic response of vascular smooth muscle cells[J]. Eur J Vase Endovasc Surg,1999; 18:417-423.
[80]Chanda J, Kuribayashi R, LiU KX, et al. Inhibitory effect of photooxidation on intimal and medial thickening of saphenous vein[J]. Ann Thorac Surg,1998; 66(2),449-454.
[81]Liu KX, Yamamoto F,Sekine S, et al.Inhibitory effect of methylene blue-induced Photooxidation on intimal thickening of vein graft[J].AnnThorac Surg,1999; 68(1):84-88.
[82]Statius RG, Mark LL, LaMuraglia GM. photodynamic therapy inhibits the injury-induced fibrotic response of vascular smooth muscle cells[J].Eur J Vase Endovasc Surg,1999; 18(5):417-423.
[83]Adili F, Statius van Eps R, Karp S, et al. Differential modulation of vascular endothelial and smooth muscle cell function by photodynamic therapy of extracellular matrix:novel insights into radical-mediated prevention of intimal hyperplasia[J]. J Vasc Surg,1996; 23:698-705.
[84]Statius van Eps RG, LaMuraglia GM. Photodynamic therapy inhibits transforming growth factor β activity associated with vascular smooth muscle cell injury [J].J Vase Surg,1997; 25:1044-1053.
[85]Hemant S. Thatte and Shukri F. Khun. The coronary artery bypass conduit:Intraoperative endothelial injury and its implication on graft pateney[J]. Ann Thorae Surg,2001; 72:2245S-2252S.
[86]Jeffrey H. Shuhaiber, Alexander N, et al.Mechanisms and future directions for Prevention of vein graft failure Incoronary bypass surgery[J]. Eur J Cardio Thorac Surg,2002; 22:387-396.
[87]刘培生,陈鑫,徐明等.不同扩张液在冠状动脉旁路移植术中对大隐静脉内皮细胞保护的对比研究[J].南京医科大学学报,2004；24：140-143.
[88]Jefrey HS, Alexander NE, Malek GM,et al. Mechanisms and future directions for prevention of vein graft failure in coronary bypass surgery[J].Eur J Cardio-Thorac Surgery,2002; 22:387-396.
[89]李寒,陈建明,张载高等.改良扩张方法对兔静脉移植物内皮细胞保护作用研究[J].心肺血管病杂志,2007；26(4),221-223.
[90]Vural KM, Oz MC, Liao H, et al. Membrane stabilization in harvested vein graft storage: effects on adhesion molecule expression and nitric oxide syntheisis[J]. Eur J Cardio Surgery,1999; 16:150-155.